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The  research  described  in  this  thesis  was  performed  at  the  department  of  Physiology, 



























































































































district  of  Eastern  Thessaly  in  Greece  (Figure  1A).  Mg  is  the  seventh  most  abundant 
element in the Earth’s crust. It is found in large deposits of magnesite, dolomite, and other 
minerals. The atom preferentially loses its two exterior electrons, to form the divalent ion 
(Mg2+)  (Figure  1B).  An  example  is magnesium  sulfate  (MgSO4)  in mineral waters, where 
Mg2+  is  soluble  (1).  In  1755  the  Scottish  Joseph  Black  found  out  that Mg  is  an  element 
itself. The British chemist Sir Humphrey Davy is seen as ‘the discoverer’ since he unraveled 
in 1808 how  to  isolate Mg  from wet MgSO4 by electrolysis.  In 1828,  the French chemist 
Antoine Bussy prepared the metal in an almost pure state. In 1833, Michael Faraday, was 



















only  1%  of  body  Mg2+  resides  in  the  extracellular  compartment,  corresponding  with  a 
serum  concentration  of  0.7‐1.1  mmol/L  (1.7‐2.2 mg/dL  or  1.5‐1.9  mEq/L)  (8,  9).  This 
suggests  that  the  free Mg2+  concentration  is  relatively  constant between  these different 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is  involved,  only  in  its  physiologically  active  ionized  form,  in many  enzymatic  reactions, 
deoxyribonucleic  acid  (DNA)  and  protein  synthesis  and  has  a  pivotal  role  especially  in 
neurons and muscular cells  (12, 13). The daily recommended dietary allowance (RDA) of 
Mg2+  intake  for an adult  is approximately 350 mg. Seeds, grains, green  leafy vegetables, 






The  plasma Mg2+  level  is maintained within  a  narrow  range  by  the  concerted  action  of 
intestinal absorption, renal excretion and exchange with bone, and disturbances in one of 
these processes can have serious consequences. First, the situation in healthy individuals 










ingested,  is  absorbed  in  a  passive  manner,  probably  depending  on  the  lumen‐positive 
electrical voltage and  the  transepithelial  concentration gradient of Mg2+  (18). The  rest  is 
absorbed via a saturable transcellular way, in which the epithelial Mg2+ channel, baptized 
transient receptor potential subfamily M, member 6 (TRPM6), is involved (18). This active 




Mg2+  is  a normal  constituent of bone and divided  in at  least  two distinct pools.  ~70%  is 
incorporated  in  the complex of hydroxyapatite crystal deposition and not exchangeable. 
The  other  ~30%  is  rapidly  exchangeable  and  elutable  (Figure  2).  This  Mg2+  reservoir  in 
bone serves as a buffer from which Mg2+ can be released or stored, as required (22). 
Importantly,  the  Mg2+  concentration  is  essential  for  bone  function.  It  influences  both 
mineral  and  matrix  metabolism;  directly  and  by  affecting  the  release  and  activity  of 
hormones,  like  parathyroid  hormone  (PTH)  and  the  active  form  of  vitamin  D 




The  kidney  is  the  most  important  organ  for  the  regulation  of  the  Mg2+  balance.  It 
accurately maintains the Mg2+ excretion via the urine and consequently the plasma Mg2+ 
level  in  response  to  changes  in  intestinal Mg2+  absorption  and  shifts  in bone absorption 






glomeruli,  since  the  remaining part  is  bound  to protein  (27,  28).  This  filtered  fraction  is 
called pro‐urine. Useful  components  and most water  (H2O) will  be  reabsorbed  from  the 
pro‐urine  to  the blood compartment and waste products are  secreted,  finally producing 
the  urine.  The  majority  of  the  filtered  Mg2+  is  reabsorbed  along  the  nephron,  the 
functional unit of the kidney, of which each kidney contains about one million structures. 
Only about 3‐5% of filtered Mg2+ is normally excreted in the urine. However, when dietary 
Mg2+  is  restricted,  the  kidney  is  capable  of  reabsorbing  almost  all  filtered  Mg2+.  Mg2+ 
reabsorption takes place  in the proximal tubule (PT),  the thick ascending  limb of Henle’s 










The  epithelial  cells  lining  the  tubular  system  are  characterized  by  their  highly  polarized 
appearance. The proteins are asymmetrically divided over two distinct membrane areas; 
the  apical  side,  facing  the  pro‐urine  and  the  basolateral  side,  facing  the  extracellular 
matrix  and  blood  vessels  (Figure  3).  These  membrane  domains,  separated  by  tight 
junctions,  have  distinct  and  clearly  defined  tasks  for  transport  of Mg2+  (29,  30).  For  the 
Dietary Mg2+
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Interestingly,  the  PCT  has  a  high  permeability  to  H2O,  sodium  (Na
+)  and  calcium  (Ca2+). 
During basal conditions only ~10% of the Mg2+ reabsorption takes place in this segment.  
A similar amount of Mg2+ is reabsorbed in the PST (34‐36). The molecular mechanism of 
this  paracellular  process  is  not  well  understood.  Mg2+  reabsorption  is  thought  to  be 
dependent  on  the  filtered  load  and Na+‐driven H2O  transport  (37,  38),  executed  by  the 
Na+, H+ exchanger 3 (NHE3) (39) and the H2O channel aquaporin 1 (AQP1) (Figure 4) (40, 
41).  
The majority, ~70% of  the Mg2+  filtered by  the glomerulus,  is  reabsorbed  in TAL  (34, 
42).  This  paracellular  reabsorption  is  driven  by  the  lumen‐positive  transepithelial 
potential, which is mainly generated by the apical Na+ and Cl‐ transport via the Na+, K+, 2Cl‐ 
























other  transporters. Exchange of  three Na+  ions  for  two K+  ions mediated by  the Na+, K+‐
ATPase,  the  apical  recycling  of  potassium  (K+)  by  the  renal  outer  medullary  K+  channel 
(ROMK)  and  the  extrusion  of  chloride  (Cl‐)  over  the  basolateral  membrane  via  the  Cl‐ 
channel,  subunit  b  (CLC‐Kb),  are  essential  for  paracellular  Mg2+  reabsorption  in  this 
nephron  segment  (42‐44).  Moreover,  tight  junction  proteins  including  claudin‐16 
(CLDN16) and claudin‐19  (CLDN19) and  in particular  their  interaction, are of  importance 
for Mg2+ diffusion through these complexes towards the blood compartment  in TAL (45‐
47).  Finally,  the  Ca2+‐sensing  receptor  (CaSR)  located  in  the  basolateral  membrane 






via  an  active  transport  process  in  the  DCT.  Noteworthy,  micropuncture  and 
microperfusion studies taught us that the capacity for Mg2+ transport in DCT is enormous 
when  needed  (26).  The  high mitochondrial  density  is  of  interest,  probably  representing 
the massive hydrolysis of ATP, necessary for accomplishment of the active transport in this 
segment  (50,  51).  In  addition,  it  has  been  shown  that  a  defect  in  the  function  of 
mitochondria results in several metabolic disorders including hypomagnesemia (52).  
The  expression  profile  of  Ca2+  and  Na+  transport  proteins  indicates  that  the  DCT 
consists  of  two  different  parts  including  the  early  DCT  (DCT1)  and  the  late  DCT  (DCT2) 
segment  (53).  DCT1  is  primarily  responsible  for Mg2+  transport, mainly  indicated  by  the 
predominant  expression  of  TRPM6  in  this  compartment  (19).  TRPM6  forms  the  apical 
entry  for Mg2+,  driven  by  a  favourable  transmembrane  potential  (26).  The  transport  of 
Mg2+ to the basolateral side of the DCT cell and its extrusion against the electrochemical 
gradient  to  the blood  side are not  completely  resolved.  It has been proposed  that Mg2+ 
crosses  the cytosol via diffusion. Possibly,  the cytosolic protein parvalbumin  (PV) plays a 
role  of  significance  and  could  act  as  a  Mg2+  buffer.  PV  originally  belongs  to  the  Ca2+‐
binding  proteins  (54),  however,  depending  on  the  physiological  conditions,  it  can  bind 











the uptake of  two K+  into  the  cytoplasm.  The  realized Na+  gradient  facilitates  the  apical 
entry  of  Na+  via  the  thiazide‐sensitive  Na+,  Cl‐  cotransporter  (NCC)  together  with  the 
uptake of Cl‐ from the pro‐urine (60). Recently, it was proposed that the voltage‐gated K+ 
channel 1.1 (Kv1.1) contributes to a favourable membrane potential by secreting K+ in the 
luminal  compartment  (Figure 4)  (61). At  the basolateral  side Cl‐  and K+  are  translocated 






into  the  interstitium via CLC‐Kb  (62,  63)  and  the  inward  rectifier K+‐channel 4.1  (Kir4.1), 
probably in complex with Kir5.1 (64), respectively. Possibly, cyclin M2 (CNNM2) is involved 
in Mg2+  transport  across  the  basolateral membrane  in  DCT  (65).  It  is  hypothesized  that 
CNNM2 senses the intracellular Mg2+ concentration ([Mg2+]i) and triggers other proteins to 
react accordingly (66). Finally, it has been shown that FXYD2 gene, encoding the γ‐subunit 
of  the Na+,  K+‐ATPase,  and  its  regulation  by  the  transcription  factor  hepatocyte  nuclear 




Figure  4.  Schematic  overview  of  proteins  associated with  electrolyte movement  in  PT,  TAL  and 
DCT  of  the  nephron,  with  the  emphasis  on  Mg2+  transport.  Mg2+  reabsorption  in  the  proximal 














































































expressed  and  crucial  for  cellular  Mg2+  homeostasis.  Previous  studies  have  shown  that 
TRPM7 is important for trafficking of TRPM6 to the plasma membrane (69‐71). However, 
the exact  composition of  the multimeric TRPM6 channels  in mammals has not yet been 
unraveled.  TRPM6  is  tightly  regulated  by  [Mg2+]i  (26)  and  by  the  dietary  intake  of Mg
2+ 
(21).  Moreover,  it  has  been  shown  that  phosphatidylinositol  4,5‐bisphosphate  (PIP2)  is 
important  for  TRPM6  activation  (72).  In  addition,  this  ion‐channel  is  modulated  by  the 
intracellular pH (73).  




important  role  as  modulator  of  TRPM6  has  been  reported  (75).  However,  the  detailed 
function  of  the  kinase  domain  remains  poorly  understood.  In  recent  years,  the  direct 
interacting  proteins,  receptor  for  activated  C‐kinase  (RACK1),  repressor  of  estrogen 
receptor activity (REA) and methionine sulfoxide reductase B1 (MsrB1) were identified as 
potential  regulators  of  the  channel  via  the α‐kinase  domain  of  TRPM6  (76‐78).  RACK1 
probably maintains a control function in Mg2+ influx in DCT by inhibition of TRPM6 channel 






large  cytosolic  amino  (NH2)  and  carboxyl  (COOH)  termini.  The  six  transmembrane  domains  are 
presumed to form a function channel with a central pore to reabsorb Mg2+. The TRPM6 interacting 
proteins and regulating  factors, as described  in  the body  text, are depicted  in  this  figure.  (B) Four 
monomers assemble, probably by heteromeric formation with TRPM7 (light blue), alternatively, four 






is not restricted to kidney and colon, but also found  in  lung (21). Despite the  interesting 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been  reported  to  play  a  role  in  the  regulation  of  the  Mg2+  balance  including  PTH, 
1,25(OH)2D3, calcitonin and glucagon (8, 32, 82‐84). These compounds, probably act in an 
indirect  manner,  via  changes  in  extracellular  volume,  acid‐base  status  or  Ca2+ 
concentration  (85,  86).  Interestingly,  estrogen  and  insulin  have been  shown  to  exert  an 
direct effect on TRPM6 (21, 87). Furthermore, our group showed that epidermal growth 
factor  (EGF),  which  is  mainly  known  for  its  role  in  cell  growth,  proliferation  and 
differentiation, can activate TRPM6 (88). Phosphorylation of  the EGF receptor  (EGFR),  in 




expression  of  TRPM6  via  phosphorylation  of  extracellular  signal‐regulated  kinases  (90). 








deficiency  can  cause  hypomagnesemia.  The  symptoms  associated  with  these  medical 
conditions will be discussed. The central focus will be on hypomagnesemia, by considering 
its  different  causes  and  appearances,  since  it  is  associated with  of  a  serious  burden  of 











lithium  and  hypothyroidism  can  result  in  hypermagnesemia  via  unknown  mechanisms 
(95). Finally, in rare cases, an overdose of Mg2+ intake via infusion, oral‐ingestion of Mg2+ 
or  treatment  with  Mg2+‐containing  cathartics  or  antacids,  resulted  in  a  serious  rise  of 












hypermagnesemia,  although  the  clinical  picture  may  comprise  neuromuscular, 
cardiovascular  and  metabolic  disturbances  like  tremor,  convolutions  and  cardiac 
arrhythmias (Table 1) (95, 98). Hypomagnesemia is diagnosed in approximately 10% of the 
hospitalized patients and can be as high as 65%  in  intensive  care patients  (92, 99, 100). 
Interestingly,  hypomagnesemia  is  often  observed  in  patients  with  chronic  diseases  like, 
diabetes mellitus type 2 (DM2), heart and vascular diseases, osteoporosis, depression and 




















In  recent  years,  genetic  investigations  of  patients  with  hereditary  forms  of 
hypomagnesemia unraveled many details of Mg2+ homeostasis, especially contributing to 
our  knowledge  of  the  DCT.  Interestingly,  besides  hypomagnesemia  the  phenotypes  of 




Finally,  the  quality  of  individual  diagnoses  is  crucial  in  order  to  obtain  the  complete 
picture.  Two  independent  groups  identified mutations  in TRPM6  as  underlying  cause  of 
the  disease  hypomagnesemia  with  secondary  hypocalcemia  (HSH).  Patients  affected  by 
this  autosomal‐recessive  disease,  were  diagnosed  early  after  birth  with  seizures  and 
tetany  (103,  104).  The  elucidation  of  the  genetic  basis  of  isolated  dominant 
hypomagnesemia  (IDH)  pointed  to  the  FXYD2  gene  (105).  Whereas,  mutations  in  its 
regulating  factor  HNF1B  are  associated  with  hypomagnesemia  combined  with  renal 
malformations,  including cysts  (67). Moreover, DNA screening of patients  suffering  from 
dominant hypomagnesemia  revealed mutations  in CNNM2  (65).  In  addition,  two groups 
independently  revealed  a  new  syndrome,  in  which  hypomagnesemia  is  one  of  the 
symptoms.  A  mutation  in  the  KCNJ10  gene,  which  encodes  Kir4.1,  was  the  underlying 
cause  (106,  107).  Besides,  EGF  was  identified  as  a  magnesiotropic  hormone,  since  a 
mutation  in  this  gene  resulted  in  isolated  autosomal  recessive  renal  hypomagnesemia 







precursor,  called  pro‐EGF  (108).  Groenestege  et  al.  showed  that  supernatant  collected 
from the basolateral  side of Madin‐Darby canine kidney  (MDCK) cells,  stably  transfected 
with mutant pro‐EGF, fails to stimulate the TRPM6 current  in TRPM6‐transfected human 
embryonic  kidney 293  (HEK293)  cells.  In  contrast,  the  apical  supernatant of  this mutant 
pro‐EGF‐transfected  cells  showed  a  similar  stimulatory  effect  as  wild  type  pro‐EGF. 
Therefore,  the  authors  hypothesized  that  the  mutation  causes  impaired  basolateral 
sorting  or  cleavage  of  pro‐EGF,  resulting  in  defective  stimulation  of  TRPM6  and 
consequently Mg2+  loss via  the urine  (88).  Finally, our group has  shown  that autosomal‐
dominant  hypomagnesemia  in  a  large  Brazilian  family  is  caused  by  a  mutation  in  the 
KCNA1 gene, encoding Kv1.1 (61).  
Also  mutations  in  proteins  involved  in  paracellular  transport  in  TAL  were  linked  to 
disturbances  of  Mg2+  homeostasis.  Patients  with  the  renal  disorder  familial 
hypomagnesemia  with  hypercalciuria  and  nephrocalcinosis  (FHHNC),  develop 




Several  inherited  disorders  exist  which  cause  hypomagnesemia  as  additional  effect. 
Bartter  and  Gitelman  syndromes  are  classical  examples.  These  syndromes  are 
characterized amongst  the salt‐losing  tubulopathies with secondary hyperaldosteronism, 






are  characterized  by  severe  Na+  and  Cl‐  wasting,  resulting  in  polyuria  and  hypokalemic 
metabolic alkalosis (111).  Interestingly, hypomagnesemia is only sporadically observed in 
antenatal Bartter syndrome (Bartter types I and II) and type IV (Table 2), whereas patients 
with  classical  Bartter  syndrome  (subtype  III)  or  type  V  are  regularly  diagnosed  with 
aberrations  in  Mg2+  homeostasis  (112‐114).  Probably,  the  degree  of  Na+  loss  is  a 
determinant  for  whether  or  not  Mg2+  reabsorption  in  TAL  is  disturbed.  However,  the 
detailed mechanism  causing  these  different  phenotypes,  concerning Mg2+  status,  is  not 
yet  resolved  (115).  Gitelman  syndrome  manifests  at  a  later  age  and  has  a  milder 


































































Drug use and malnutrition are  the most  important  causes of acquired hypomagnesemia 




Diuretics are drugs  that  induce Na+ wastage and secondary H2O  loss. They are generally 
prescribed  in the treatment of hypertension and edema. A well‐known adverse effect of 
diuretics is the development of hypomagnesemia. Loop diuretics inhibit the reabsorption 
activities  of  the  TAL.  For  example,  furosemide‐treatment  might  result  in  a  similar 
phenotype  as  antenatal  Bartter  syndrome,  caused  by  blocking  NKCC2  (119). Within  the 
first  hours  after  a  single  dose  of  furosemide,  urinary  Mg2+  excretion  is  significantly 
increased  (125, 126). However,  like  for antenatal Bartter  syndrome, hypomagnesemia  is 
not  regularly diagnosed  in patients  chronically  treated with  furosemide;  the Mg2+  status 
seems  to  depend  mainly  on  the  general  state  of  health  of  these  patients  (127‐130). 
Thiazide  diuretics  act  on  NCC,  causing  equivalent  symptoms  as  observed  for  Gitelman 
syndrome  (120).  The  anticancer  drug  cis‐diamminedichloroplatinum(II)  (cisplatin)  is  a 
potent agent for the treatment of solid tumors. This compound induces hypomagnesemia 
in  about  50%  of  the  patients  treated,  depending  on  dosage,  amount  of  cycles  and 






immunosuppressive  agents  with  nephrotoxicity  and  hypomagnesemia  as  iterative  side 
effects. Moreover, antimicrobials, with gentamycin, rapamycin and pentamidine as most 
prominent  examples  can  affect Mg2+  homeostasis  as well  (Table 2)  (118).  In  contrast  to 









of Mg2+  (Table  2)  (124).  Frequently,  drug  use  indirectly  results  in  these  gastrointestinal 
problems,  however,  impaired  Mg2+  absorption  can  also  be  induced  directly  by 
characteristic  diseases  of  this  organ  like  gastrointestinal  fistulas  or  inflammatory  bowel 











explains  the underlying mechanism  (135). A defect  in TRPM6, might  form the molecular 
basis  (87). Heart and vascular diseases, another major contributor  to decreased  lifespan 
and rising health care costs, probably results in hypomagnesemia due to comorbidity, like 
renal insufficiency or via treatment with diuretics or surgery (136‐138). In addition, it has 
been suggested that Mg2+ deficiency  is a risk  factor  for some types of cancer and that  it 
plays  a  role  in  progression  of  the  disease  or  complicates  (drug)  therapy  (139). 







cations.  Some  binding  proteins  like  PV  can,  although  the  affinities  are  generally  quite 
different,  interact  with  both  divalents  (55,  57).  Subsequently,  active  transport  of  these 
electrolytes  is  executed  by  transporters  of  the  same  transient  receptor  potential  (TRP)‐
family (144). In addition, diffusion through the tight junctions in TAL for example does not 
discriminate  between  Ca2+  and  Mg2+  ions  (145).  However,  often  these  ions  exert 
antagonistic  biological  actions  or  modulate  each  other’s  actions  (146‐148).  Mainly, 
because Ca2+  ions dehydrate easily compared  to Mg2+, which  is more soluble,  these  ions 




Maintenance of  the Ca2+  balance  is  of  vital  importance,  especially  for  a  lot of  brain  and 
heart  physiological  functions  (35).  Similar  to  the  regulation  of  the  Mg2+  balance,  the 
concerted  role  of  bone,  intestine  and  kidney  is  vital.  Ca2+  is  in  part  absorbed  more 
proximal in the intestine compared to Mg2+, in fact largely in the duodenum (35, 150). This 
process  is  dependent  on  the  gradient  created  by  the  Na+  and  H2O  absorption  (151).  In 
addition,  renal  Ca2+  reabsorption  is  slightly  different  from  Mg2+  reabsorption.  The  PT 




cytosol,  in  association with  calbindin‐D28K  to  the  basolateral  cell membrane, where  it  is 
extruded by  the Na+, Ca2+‐exchanger  (NCX1) and  the plasma membrane ATPase  type 1b 
(PMCA1b) (35, 152). Ca2+ homeostasis is maintained by the four calciotropic hormones: i) 
PTH;  ii)  1,25(OH)2D3;  iii)  calcitonin and;  klotho  (35,  151,  153,  154). Ca
2+  influx  via  TRPV5 
and its relative TRPV6 is an important regulatory target of PTH and 1,25(OH)2D3 (155). PTH 
activates TRPV5 via protein  kinase A  (PKA)  signaling and  subsequent phosphorylation of 
the carboxyl  tail  (156). Besides, PTH  is  involved  in  the mobilization of Ca2+  from  in bone 
and  stimulation of  Ca2+  absorption  in  the  intestine  via  1,25(OH)2D3  (157).  PTH  release  is 
regulated  by  the  parathyroid  gland,  in  response  to  changes  in  the  plasma  Ca2+ 
concentration.  The  CaSR  has  a  central  role  in  this  process  (157,  158).  In  response  to  a 
reduced  extracellular  Ca2+  or  Mg2+  level,  the  CaSR  is  less  activated,  which  results  in  a 
relatively low intracellular Ca2+ concentration ([Ca2+]i) and subsequent release of PTH into 






the  circulation  from  the  cells  of  the  parathyroid  gland  (157,  159,  160).  This  hormonal 
regulation  is  of  special  interest,  since  there  is  a  lot  of  evidence  that  these  hormones 
influence Mg2+  homeostasis  as well  (161).  Besides,  it  has  been  shown  that  dietary Mg2+ 
restriction  not  only  leads  to  renal Mg2+  conservation,  but  also  to  Ca2+  conservation  and 
that vise versa, a Mg2+‐enriched diet leads to increased excretion of both electrolytes (21). 
This  close  interaction  of  Mg2+  and  Ca2+  homeostasis  is  in  line  with  the  longstanding 
observation  of  the  development  of  hypocalcemia,  in  patients  and  animals  with 
hypomagnesemia  (25).  The  disease  HSH,  in  which  patients  are  affected  by  a  non‐
functional TRPM6 channel, represents an example of this phenomenon (103, 104).  It has 





Hypokalemia  is  probably  the  most  common  electrolyte  disturbance  encountered  in 
hospitalized  patients,  with  an  incidence  of  around  20%.  The  clinical  importance  is,  that 
severe aberrations  in K+ balance may predispose  the patient  to  cardiac  arrhythmias  and 
paralysis  (165).  The  extracellular  and  intracellular  K+  concentrations  are  essential 
components  in  skeletal  muscle,  cardiovascular  and  respiratory  function  by  setting  the 
membrane potential and propagation of action potentials (166). Like for Mg2+, the kidney 
is  the  most  important  overall  regulator  of  K+  homeostasis,  by  adjusting  the  rate  of  K+ 
excretion. Hypokalemia  is  in most patients of multifactorial nature, with gastrointestinal 
losses due to vomiting or diarrhea, or increased renal excretion of K+ initiated by thiazide 
or  loop  diuretics  like  furosemide,  usually  included.  In  around  60%  of  the  patients 















hypomagnesemia.  As  described  in  the  previous  paragraphs,  recent  studies  considerably 














on  Mg2+  homeostasis.  It  is  reported  that  the  chronic  use  of  this  compound  in  mice  is 




their  susceptibility  to  dietary  Mg2+  content.  Besides  TRPM6,  HNF1B  was  shown  to  be 
upregulated  in  hypomagnesemic  mice.  It  was  demonstrated  that  NCC  and  PV,  both 
expressed  in  DCT,  were  affected  by  the  Mg2+  status.  In  addition,  molecular  players 
responsible  for  the  association  of  renal  Ca2+  and  Mg2+  transport  were  examined.  In 
Chapter 5 the fate of the mutation in pro‐EGF, causing hypomagnesemia in patients was 
investigated.  The  cellular  sorting  of  pro‐EGF  and  secretion  of  its  different  cleavage 
products  was  studied  in  transfected  cell  lines  and  the  surrounding  culture medium.  To 
unravel  this  shedding  process  in  detail,  immunoblotting,  enzyme‐linked  immunosorbent 
assay  and  immunocytochemistry  followed  by  confocal  microscopy  analysis,  were  used. 
Finally, in Chapter 6 the main findings of this thesis are summarized, and the conclusions 
and future directions are discussed. 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to  dose‐dependent  nephrotoxicity.  The  majority  of  cisplatin‐treated  patients  develop 
hypomagnesemia,  often  associated  with  a  reduced  glomerular  filtration  rate  (GFR), 
polyuria  and  other  electrolyte  disturbances.  The  aim  of  this  study  is  to  unravel  the 
molecular mechanism responsible for these particular electrolyte disturbances.  
Methods. Two groups of 10 mice were injected intraperitoneally three times, once every 4 
days,  with  cisplatin  (5  mg/kg  body  weight,)  or  vehicle.  Serum  and  urine  electrolyte 
concentrations  were  determined.  Next,  renal  mRNA  levels  of  distal  convoluted  tubule 
(DCT)  genes  epithelial  Mg2+  channel  TRPM6,  the  Na+,  Cl‐  cotransporter  (NCC),  and 
parvalbumin (PV), as well as marker genes for other tubular segments were measured by 





0.02  and  0.26  ±  0.02  mL/min,  cisplatin  versus  control,  P  <  0.05)  and  a  substantially 
reduced serum level of Mg2+ (1.23 ± 0.03 and 1.58 ± 0.03 mmol/L, cisplatin versus control, 
P < 0.05), whereas serum Ca2+, Na+ and K+ values were not altered. Measurements of 24 h 
urinary  excretion  demonstrated markedly  increased Mg2+,  Ca2+,  Na+  and  K+  levels  in  the 
cisplatin‐treated group, whereas Pi  levels were not changed. The mRNA levels of TRPM6, 
NCC and PV were significantly reduced in the cisplatin group. The expression levels of the 
marker  genes  for  other  tubular  segments  were  unaltered,  except  for  claudin‐16,  which 























range  of  actions  in  the  treatment  of  solid  tumours,  including  ovarian,  endometrial, 
cervical,  urothelial,  testicular,  head/neck  and  lung  cancer  (1).  Cisplatin  causes  cytotoxic 
lesions  in  rapidly dividing cells,  such as  tumour cells, due  to  the  formation of cross‐links 
with RNA, DNA and protein  (2). Despite  its effect as an anti‐cancer agent,  clinical use  is 
limited  as  ~20%  of  the  patients  who  receive  high‐dose  cisplatin  develop  severe  renal 
dysfunction, often leading to acute renal failure (3‐5). DNA‐damaging agents usually have 
a  less  toxic effect on non‐proliferating  cells,  yet,  selective  tubular epithelial  cell  damage 
has  been  demonstrated.  Treatment  with  cisplatin  or  related  compounds  cause  tissue 
damage  by  inflammation,  oxidative  stress  injury,  necrosis  and/or  apoptosis  (4)  of 
particularly the renal proximal tubule (PT) (6, 7) and/or the distal convoluted tubule (DCT) 
(8‐13)  in  humans  and  a  variety  of  animal models.  The  renal  phenotype  associated with 
treatment of  cisplatin  is multifold.  The majority of  cisplatin‐treated patients  suffer  from 
hypomagnesemia  (14,  15),  often  associated  with  a  reduced  glomerular  filtration  rate 
(GFR),  polyuria  and  electrolyte  disturbances  such  as  sodium  (Na+),  calcium  (Ca2+)  and 
magnesium  (Mg2+)  wasting  and/or  hypokalemic  alkalosis  (16‐19).  Previously,  it  was 
suggested  that  the  DCT  could  play  a  prominent  role  in  causing  cisplatin‐induced 
hypomagnesemia (20‐22). 
The observed nephrotoxicity  likely results  from cisplatin accumulation  in the kidneys, 
which is five times higher in comparison with other tissues. Although platinum compounds 
are bound to proteins in the plasma, most cisplatin is unbound (5) and is freely filtered by 




Cisplatin  enters  the  tubular  cell  by  passive  diffusion  and  active  uptake  via  specific 
transport mechanisms (25). 
The  present  study  aims  to  elucidate  the  molecular  mechanism  responsible  for  the 
cisplatin‐induced  hypomagnesemia.  In  recent  years,  the  study  of  patients  with 
hypomagnesaemia has led to the identification of genes involved in Mg2+ handling. A large 
fraction  of  these  genes  localize  to  the  early  part  of  the  DCT  (DCT1),  indicating  its 
prominent  role  in Mg2+  reabsorption  (26). Examples are  the  transient  receptor potential 
channel melastatin subtype 6 (TRPM6), the epidermal growth factor, the voltage‐gated K+ 
channel  Kv1.1  and  the  Na+,  K+‐ATPase  γ‐subunit. We  hypothesize  that  cisplatin‐induced 
hypomagnesemia is caused by specific damage to the DCT. The effect of chronic cisplatin 
treatment on serum Na+, potassium (K+), Ca2+ and Mg2+ and urine Na+, K+, Ca2+, Mg2+ and 

















Female C57BL/6J mice  (10 weeks of age) were purchased  from Charles River  (L’Arbresle 
Cedex,  France)  and housed  in  a  temperature‐  and  light‐controlled  room with ad  libitum 
access to standard pellet chow (SSNIFF spezialdiäten GmbH, Soest, Germany) and drinking 
water. Mice were randomly assigned to a control and a cisplatin treatment group (n = 10 
per  group).  Cisplatin was  administered using  an  intraperitoneal  injection  (5 mg/kg body 
weight per injection), while control animals received an intraperitoneal injection of vehicle 
only  (0.9%  (w/v)  NaCl  solution).  The  injections  were  administrated  on  days  0,  4  and  8. 
Before the start of the experiment, and on day 12, the mice were  individually housed  in 
metabolic cages enabling 24 h urine collections (under mineral oil to prevent evaporation) 
and  to  measure  water  and  food  intake.  On  day  13,  blood  samples  were  taken  under 
isoflurane anaesthesia, after which the mice were sacrificed. Subsequently, kidneys were 
frozen  immediately  in  liquid nitrogen or  incubated  in periodate‐lysine‐paraformaldehyde 
(PLP)  solution  for  the  isolation  of  mRNA  and  protein  or  immunohistochemistry  (IHC) 
analysis, respectively. Blood was led to clot at room temperature, incubated overnight at 
4°C and spun down for 5’ at 13 250 × g. The serum was collected and used for analytical 













standard  procedures  (Gibco  BRL,  Breda,  The  Netherlands).  The  obtained  RNA  was 
subjected  to  DNase  treatment  (Promega,  Madison,  WI,  USA)  to  prevent  genomic  DNA 
contamination.  All  samples  were  resolved  on  a  1%  w/v  formaldehyde  agarose  gel  to 
evaluate  the  RNA  quality,  while  RNA  concentration  was  determined  by  measuring  the 
ratio  of  the  UV  absorbance  at  260  and  280  nm  using  the  NANODROP  2000c  (Thermo 
scientific,  Wilmington,  DE,  USA).  Thereafter,  1.5  µg  of  RNA  was  reverse  transcribed  by 




Total  kidney  cDNA  was  used  to  determine  the  mRNA  expression  levels  of  genes  of 
interest,  as  well  as  the  reference  gene  glyceraldehyde  3‐phosphate  dehydrogenase 
(GAPDH).  Primer3  software  (http://frodo.wi.mit.edu/primer3/)  was  used  to  design  real‐
time  quantitative  polymerase  chain  reaction  (qPCR)  primers  according  to  the  general 
criteria for real‐time primers. All primer sequences used in this study are listed in Table 1 





efficiency  (95‐105%)  and  dynamic  range  (R2>0.98)  were  evaluated  for  each  primer  set. 
Real‐time qPCR reactions were performed on a Bio‐Rad CFX96™ Real‐Time qPCR and Bio‐

























dehydrogenase;  Kim‐1,  Kidney  injury  molecule‐1;  TRPM6,  transient  receptor  potential  melastatin 
member 6; PV, parvalbumin; NCC, Na+, Cl‐  cotransporter; NKCC2, Na+, K+, Cl‐  cotransporter; NHE3, 
Na+, H+ exchanger 3; CLDN16, claudin‐16; CLDN19, claudin‐19; AQP1, aquaporin 1; SGLT1, sodium‐
glucose  cotransporter  1;  TRPV5,  transient  receptor potential  vanilloid member; α‐ENaC,  epithelial 






A  (HbA;  20 mM Tris/HCl  (pH = 7.4),  5 mM MgCl2,  5 mM NaH2PO4,  1 mM EDTA,  80 mM 
sucrose, 1 mM PMSF, 1 µg/ml leupeptin and 10 µg/ml pepstatin). Protein concentration of 














Figure  1.  Schematic  overview  of  a  nephron  depicting  the  expression  of  gene  products  used  as 
marker  to  determine  in  which  segments  cisplatin  exerts  its  effect.  Nephron  segments:  PCT, 
proximal convoluted tubule; PST, proximal straight tubule; TAL, thick ascending limb of Henle’s loop; 
DCT, distal convoluted tubule; CNT, connecting tubule; CD, collecting duct. Gene products used as 
marker:  NHE3,  Na+,  H+  exchanger  3;  AQP1,  aquaporin  1;  SGLT1,  sodium‐glucose  cotransporter  1; 
NKCC2,  Na+,  K+,  Cl‐  cotransporter;  CLDN16,  claudin‐16;  CLDN19,  claudin‐19;  TRPM6,  transient 




Billerica,  MA,  USA),  a  rabbit  parvalbumin  antibody  (PV‐28,  1:500  dilution;  Swant, 
Bellinzona,  Switzerland),  and  a mouse monoclonal  aquaporin  1  (AQP1)  antibody  (1:100 
dilution)  (28),  a  rabbit  aquaporin 2  (AQP2)  antibody  (1:500 dilution) or  a mouse  tubulin 
antibody (1:20 000 dilution); (these antibodies were provided by Prof. Deen). Thereafter, 
blots  were  incubated  with  peroxidase‐conjugated  secondary  antibodies  after  which 
proteins  were  visualized  by  chemiluminescence  (Pierce,  Rockford,  IL,  USA). 
Immunopositive  bands  were  scanned  using  ChemiDoc  XRS  (Bio‐Rad)  and  signals  were 












Data  are  expressed  as  mean  ±  SEM.  Overall  statistical  analyses  were  performed  by 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urinary  creatinine  excretion  (Table  3),  indicating  a  significantly  reduced  creatinine 
clearance  (CCr)  (Table  3).  The  excretion  of  Mg
2+,  Ca2+,  Na+,  K+  and  Pi  was  corrected  by 
urinary concentration of creatinine to compensate for changes in GFR. In comparison with 
the  control  group,  the  renal  excretion  of  Mg2+,  Ca2+,  Na+  and  K+  was  increased  on 





To  evaluate  whether  cisplatin  treatment  caused  tubular  injury,  the  expression  level  of 


































on  days  0,  4  and  8;  CCr,  creatinine  clearance.  Values  are  presented  as  average  ±  SEM. 










kidney  injury.  The  effect  of  cisplatin  (5 
mg/kg/injection  on  days  0,  4  and  8)  on 
mRNA  expression  levels  of  kidney  injury 
molecule‐1 (Kim‐1). Results are presented 
as average ± SEM (n = 10), relative to the 














































Na+  transporters  as  well  as  AQP2,  were  determined  by  real‐time  qPCR  (Figure  3).  The 
cisplatin group showed significantly  lower expression  levels of TRPM6 (60 ± 7 and 100 ± 
5%,  cisplatin  versus  control,  P  <  0.05)  and  NCC  (63  ±  7  and  100  ±  5%,  cisplatin  versus 
control, P < 0.05). Additionally, the DCT specific protein PV was markedly downregulated 
in  cisplatin‐treated  mice  (38  ±  12  and  100  ±  6%,  cisplatin  versus  control,  P  <  0.05). 
Subsequently, the mRNA expression levels of the Na+, K+, 2Cl‐ cotransporter (NKCC2) and 
the tight  junction proteins claudin‐16 (CLDN16) and claudin‐19 (CLDN19) (31), all  located 
in  the  thick  ascending  limb  of  Henle’s  loop  (TAL),  were  determined.  The  NKCC2  and 









The effect of  cisplatin  (5 mg/kg/injection on days 0,  4  and 8) on mRNA expression  levels of  renal 
transport proteins, which  reside  in  the distal  convoluted  tubule  (DCT),  such as  the epithelial Mg2+ 
channel TRPM6, the Na+, Cl‐ cotransporter (NCC) and parvalbumin (PV) or are located in other tubule 
segments,  including  the  Na+,  K+,  Cl‐  cotransporter  (NKCC2),  claudin‐16,  (CLDN16),  claudin‐19 
(CLDN19), the Na+, H+ exchanger 3 (NHE3), aquaporin 1 (AQP1), the sodium‐glucose cotransporter 1 











































































































Moreover,  the mRNA expression  levels of AQP1, expressed  in  the PCT and  the proximal 
straight  tubule  (PST)  and  of  the  sodium‐glucose  cotransporter  1  (SGLT1),  exclusively 
expressed in the PST, were also unaffected by cisplatin treatment (96 ± 6 versus 100 ± 5% 
for  AQP1  and  98  ±  3  versus  100  ±  5%  for  SGLT1,  cisplatin  versus  control,  P  >  0.2).  The 
mRNA level of the late DCT (DCT2) and CNT marker TRPV5 was not changed either upon 
cisplatin treatment (122 ± 11 and 100 ± 5%, cisplatin versus control, P > 0.2). Furthermore, 
the mRNA  level  of  the  epithelial  Na+  channel  (ENaC),  which  localizes  to  the  connecting 
tubule  (CNT)  and  collecting duct  (CD), was not  significantly  changed by  cisplatin  (89 ± 5 





The  effect  of  cisplatin  treatment  on  NCC,  PV,  AQP1  and  AQP2  protein  expression  was 
investigated  by  immunoblotting.  We  were  able  to  confirm  the  DCT‐specific 
downregulation on protein  level. NCC and PV were significantly reduced  in the cisplatin‐ 





Next,  to  establish whether  the  reduction  of mRNA  encoding  for  DCT  transporters  is 
dependent  on  protein  downregulation  or  on  cellular  damage  immunohistochemical 
staining was performed for NCC and PV. Figure 5 shows that NCC and PV are localized in 
the same cell compartment when treated with cisplatin, compared with control mice. It is 










Figure  4.  Effect  of  cisplatin  on  protein  expression  levels  of  renal marker  proteins. The  effect  of 
cisplatin  (Cisp)  (5 mg/kg/injection on days  0,  4  and 8)  on protein  expression  levels  of  the Na+,  Cl‐ 
cotransporter (NCC) (A), parvalbumin (PV) (B), aquaporin 1 (AQP1) (C) and aquaporin 2 (AQP2) (D). 
The upper part of each figure shows the immunoblot, with on the left side the molecular mass (in 
kDa)  and  the  lower parts  depict  the expression  levels  as  percentage of  control  (Cont).  Values  are 

















































































































































Figure  5.  Effect  of  cisplatin  on 
protein expression of NCC and 
PV  in  kidney.  The  effect  of 
cisplatin  (5 mg/kg/injection  on 
days  0,  4  and  8)  on  protein 
expression  levels  and 
localization  of  the  Na+,  Cl‐ 
cotransporter  (NCC)  and 
parvalbumin  (PV)  in  mice 
kidney was  studied. This  figure 
shows representative images of 








the damage to particularly  this  tubule segment. The organic cation transporter 2  (OCT2) 
and the copper transporter 1 (CTR1) are identified to contribute to the uptake of cisplatin 
(36,  37).  The  mRNA  expression  level  of  OCT2  was  not  changed  in  the  cisplatin  group, 
compared with the control group (93 ± 10 and 100 ± 7%, cisplatin versus control, P > 0.2) 














levels  are  shown  as  percentage  of 
control.  Values  are  presented  as 
average ±  SEM  (n = 10).  * P < 0.05 









































































Our  study  provides  further  evidence  that  the  DCT  segment  is  affected  by  cisplatin 
treatment. We demonstrated that cisplatin treatment  in mice  induces hypomagnesemia, 









The DCT plays  a  key  role  in determining  the  final  plasma Mg2+  concentration,  as  the 
more  distal  parts  of  the  tubule  are  largely  impermeable  to  Mg2+.  In  DCT,  Mg2+ 
reabsorption  occurs  in  an  active  transcellular  manner  initiated  by  TRPM6  (38).  TRPM6 
localizes  to  the  luminal membrane  where  it  facilitates  transport  of Mg2+  from  the  pro‐
urine into the cell (39). The importance of Mg2+ in cisplatin‐induced renal injury has been 





the  thiazide  diuretics,  which  are  commonly  prescribed  drugs  in  the  treatment  of  high 
blood pressure (43). 
Furthermore,  the  effect  of  cisplatin  treatment  on  mRNA  and  protein  expression  in 
other  tubule  segments,  including PT,  TAL, CNT and CD, was  investigated.  The PT  can be 
severely affected by cisplatin treatment, especially morphological changes in the PST have 
been observed (6, 7). The cisplatin‐induced increase of the Kim‐1 expression level suggests 
that  the PST  segment  is  also  affected  in  our  study  (30,  44).  The NHE3 expression  levels 
were  similar  in  the  kidneys  of  control  and  cisplatin‐treated  groups.  IHC  for  NHE3 
previously showed strong staining on the apical membrane of the PCT, while staining was 
absent  in  the  PST  (32).  Therefore,  we  also  determined  the  mRNA  expression  level  of 
SGLT1,  which  is  exclusively  expressed  in  the  PST  segment  (45),  and  of  AQP1,  which  is 
present  throughout  the  PT  (46).  However,  also  for  these  genes  we  did  not  observe  a 







unchanged  following  cisplatin  treatment.  Our  observations  are  in  line  with  a  study  by 
Ecelbarger et al. which showed normal protein expression of NKCC2 in the medullary TAL 
segment  (48).  The  same  study  also  demonstrated  that  the  protein  abundance  of NHE3, 
the renal outer medullary K+ channel (ROMK), localized in TAL and CNT and the α‐subunit 










was  reduced.  This  is  in  contrast  with  our  results,  which  showed  no  effect  of  cisplatin 
treatment on AQP2 mRNA and protein level. Remarkably, a study by Lajer et al. displayed 
lower protein abundance for all investigated proteins, including the α‐subunit of the Na+, 
K+‐ATPase,  NHE3,  NKCC2,  AQP1  and  AQP2  (40).  It  is  important  to  note  that  these 
discrepancies may result from a species‐specific effect because they all used rats reporting 
a more severe polyuria. Proper  interaction of CLDN16 and CLDN19 in TAL is essential for 
the  cation  selectivity  of  paracellular  route  and  consequently  reabsorption  of  divalent 
cations in this tubule segment (31). Upregulation of CLDN16 levels in our cisplatin‐treated 
mouse group suggested that TAL might compensate for decreased reabsorption of Mg2+ in 
DCT. Altogether, our  results  suggest a  specific downregulation of proteins  that  reside  in 
the  DCT.  To  our  knowledge,  this  is  the  first  study  that  specifically  investigates  the 
expression levels of transport proteins in the DCT following cisplatin treatment.  
There  are  several  mechanisms  that  can  explain  the  polyuria,  which  is  caused  by 
cisplatin  administration.  In  rats  it  has  been  shown  that  polyuria  is  associated  with 
decreased  expression  of  AQP1,  2  and  3  (49). However, we  did  not  observe  a  change  in 
mRNA  or  protein  level  of  AQP1  and  AQP2.  Additionally,  IHC  staining  displayed  similar 
AQP2 localization and quantity in kidneys of cisplatin‐treated or control animals (data not 
shown).  We  also  determined  whether  the  polyuria  might  be  secondary  to  osmotic 
diuresis. As depicted in Table 3, the urinary osmolality is markedly reduced after cisplatin 
treatment  that  renders  this  assumption  unlikely.  Reduced  urinary  osmolality  in 
combination with a decline of CCr indicate decreased GFR due to acute kidney failure in the 
cisplatin‐treated animals. Another explanation might, therefore, be that a decreased GFR, 
secondary  to  cisplatin‐induced  nephrotoxicity,  is  associated with medullary  urea  cycling 
defect.  This  results  in  reduced  tonicity  of  the medulla  and  as  a  consequence  increased 
excretion  of  water  (4).  Moreover,  we  showed  that  cisplatin  treatment  causes 
hypomagnesemia  and  increased  urinary  excretion  of  K+  and  Na+  in  combination  with 
polyuria. Interestingly, in patients suffering from Gitelman Syndrome (GS), besides tetany 
and  muscle  weakness,  similar  findings  were  observed  (16,  18,  50).  GS  results  from 











Taken together, our study  identified  for  the  first  time a specific effect of cisplatin on 
the  expression  level  of  DCT  markers.  It  is  unclear  whether  this  is  caused  by  specific 
downregulation of Na+ and Mg2+ transport proteins in the DCT or a cisplatin‐induced DCT‐
specific  cell  death.  The  procedure  for  cisplatin‐mediated  cell  death  is  still  unknown. 
Apoptosis can be induced by the formation of chromosomal DNA/cisplatin adducts and/or 
mitochondria‐induced pathways (56, 57). Mitochondria‐induced apoptosis is of interest as 




the  large  size  and  high  density  of  mitochondria  characterizes  DCT  cells  (58).  For  that 
reason,  the DCT may be more  susceptible  to mitochondria‐induced apoptosis,  as  shown 
for  cell  lines  with  a  relatively  high  density  of  mitochondria  (59).  Alternatively,  as  only 
minor  cellular  damage was  detected,  specific  down‐regulation  of  proteins  in  DCT might 
indeed be the mechanism causing loss of function of this part of the nephron. 
Research focuses on the identification of cisplatin transport mechanism contributing to 
its  segment  specific  nephrotoxicity  and  ways  to  block  these  in  a  competitive  manner. 
Recent studies identified OCT2 (36) and the copper transporter 1 (CTR1) (37) as cisplatin‐
transporting proteins.  Interestingly, both OCT2 and CTR1 are expressed  in  the kidney as 
well as  in malignant  tissues  (60‐62) and are,  for  that  reason,  candidates  to  facilitate  the 
entry of cisplatin into renal cells. Our results showed that the mRNA level of OCT2 was not 
affected,  whereas  the  CTR1  expression  level  was  slightly  but  significantly  decreased  by 
cisplatin treatment. Recently, Pabla et al. identified PKCδ as a critical regulator of cisplatin 
nephrotoxicity (63). Future studies are needed to confirm the role of CTR1 in the entry of 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Background.  Furosemide  is  a  loop  diuretic, which  blocks  the Na+,  K+,  2Cl‐  cotransporter 
(NKCC2)  in  the  thick  ascending  limb  of  Henle’s  loop  (TAL).  By  diminishing  sodium  (Na+) 
reabsorption,  loop  diuretics  reduce  the  lumen‐positive  transepithelial  voltage  and 
consequently  diminish  paracellular  transport  of magnesium  (Mg2+)  and  calcium  (Ca2+)  in 
TAL. Indeed, furosemide promotes urinary Mg2+ excretion; however, it is unclear whether 
this  leads,  especially  during  prolonged  treatment,  to  hypomagnesemia.  The  aim  of  the 
present  study was,  therefore,  to determine  the effect of  chronic  furosemide application 
on renal Mg2+ handling in mice.  
Methods.  Two  groups  of  10 mice  received  an  osmotic minipump  subcutaneously  for  7 
days  with  vehicle  or  30  mg/kg/day  furosemide.  Serum  and  urine  electrolyte 
concentrations were determined. Next, renal mRNA levels of the epithelial Mg2+ channel 
(TRPM6),  the  Na+,  Cl‐  cotransporter  (NCC),  the  epithelial  Ca2+  channel  (TRPV5),  the 
cytosolic Ca2+‐binding protein calbindin‐D28K, as well parvalbumin (PV), claudin‐7 (CLDN7) 
and  claudin‐8  (CLDN8),  the  epithelial  Na+  channel  (ENaC)  and  the  Na+,  H+  exchanger  3 
(NHE3)  were  determined  by  real‐time  quantitative  polymerase  chain  reaction  (qPCR). 
Renal  protein  levels  of  NCC,  TRPV5,  calbindin‐D28K  and  ENaC were  also measured  using 
semi‐quantitative immunohistochemistry (IHC) and immunoblotting.  
Results.  The  mice  chronically  treated  with  30  mg/kg/day  furosemide  displayed  a 
significant  polyuria  (2.1  ±  0.3  and  1.3  ±  0.2  mL/24h,  furosemide  versus  control 
respectively, P < 0.05). Furosemide treatment resulted in increased serum concentrations 
of Na+ (158 ± 3 (treated) and 147 ± 1 mmol/L (control), P < 0.01), whereas serum K+, Ca2+ 


















thick  ascending  limb of Henle’s  loop  (TAL)  (1) by  competing  for  the  chloride  site on  the 
transporter  (2).  Interestingly,  most  magnesium  (Mg2+)  reabsorption  takes  place  in  TAL 
(~60  %)  in  a  passive,  paracellular  way  (3,  4).  This  reabsorption  is  driven  by  the 
transepithelial  potential  mediated  by  transport  via  NKCC2.  Furosemide  treatment  is 
usually  prescribed  primarily  for  its  natriuretic  action  as  treatment  of  edematous  status 
and  hypertension  (5).  By  diminishing  sodium  (Na+)  reabsorption,  the  concentrating 
process  that occurs  in  the  renal medulla  is  impaired and  fluid  loss ensues. On  the  short 
term, this results in diminished Na+ and chloride (Cl‐) reabsorption and as a consequence, 
due  to  increased  distal  Na+  delivery  and  increased  levels  of  aldosterone,  potassium  (K+) 
loss.  In  TAL,  the  generation  of  a  lumen‐positive  transepithelial  voltage  by  NKCC2  is 
diminished  by  treatment  with  furosemide,  consequently  paracellular  transport  of  Mg2+ 
and calcium (Ca2+)  is  reduced resulting  in  increased urinary excretion of  these  ions  (6‐8). 
Chronic  effects  of  furosemide  treatment  sometimes  result  in  hypercalciuria,  but  only 
rarely leading to hypocalcemia (9, 10). Long‐term effects of treatment with furosemide on 
urinary  and  serum Mg2+  values  vary,  in  such  a way  that  hypomagnesemia  is  sometimes 
observed  in patients with heart  failure or other  serious diseases, while especially during 
sufficient Mg2+ intake disturbances in Mg2+ balance are not generally observed (9, 11, 12). 
However,  data of  chronic  furosemide  treatment  in healthy  volunteers or  animal models 
are scarce and seem to lack analysis of Mg2+ homeostasis in relation to other electrolytes. 
A  complicating  factor  of  chronic  furosemide  use  is  the  development  of  resistance, 




resistance  develops  due  to  the  short‐acting  characteristic  of  furosemide,  with  a  peak 
plasma  concentration  after  ~1  h  of  furosemide  treatment  (18,  19).  Thus,  increased 
reabsorption  of  Na+  can  be  observed  rapidly,  know  as  the  ‘rebound  phase’  (14).  As  an 
indicator  of  resistance  to  chronic  furosemide  treatment,  particularly  the  impaired 
natriuretic  response was  determined  by measuring  renal  Na+  excretion  levels  (15).  It  is 




hereditary  recessive  disease,  which  impairs  the  transport  function  of  the  TAL,  is 
characterized  by  prenatal  onset,  a  severe  salt‐wasting  state  with  low  blood  pressure, 
hypokalemic  metabolic  alkalosis,  hyperreninemia,  polyuria,  hyperprostaglandinuria  and 
often hypercalciuria (21). 
The aim of  the present  study was  to unravel whether  chronic  furosemide  treatment 
leads  to  hypomagnesemia  or  that  other  parts  of  the  nephron  can  compensate  for  the 
reduced Mg2+ reabsorption  in TAL. For this purpose, the chronic effect of  furosemide on 
renal handling of Mg2+ was studied in mice. The fine‐tuning of Mg2+ excretion is mediated 
by  the  early  DCT  (DCT1),  where  active  transcellular  reabsorption  takes  place  via  the 














Male  C57BL/6J  mice  (10  weeks  of  age)  were  purchased  from  Harlan/CPB  (Zeist,  The 
Netherlands)  and  roomed  in  a  temperature‐  and  light‐controlled  room  with  ad  libitum 
access  to  standard  pellet  chow  (0.19%  w/w  Mg2+,  SSNIFF  spezialdiäten  GmbH,  Soest, 
Germany) and drinking water. Mice were randomly assigned to a control and a furosemide 





experiment, blood  samples were  taken under  isoflurane anaesthesia and  the mice were 
sacrificed. Subsequently, kidneys were frozen immediately in liquid nitrogen or incubated 
in  periodate‐lysine‐paraformaldehyde  (PLP)  solution  for  RNA  isolation,  immunoblotting 
and  immunohistochemistry  (IHC)  analysis,  respectively.  Blood  was  led  to  clot  at  room 





Serum  Mg2+  concentration  and  urinary  Mg2+  excretion  were  determined  using  a 
colorimetric  assay  kit  according  to  the  manufacturer’s  protocol  (Roche  Diagnostics, 
Woerden,  The  Netherlands).  Serum  and  urine  Ca2+  concentrations  were  measured 




Total  RNA  was  extracted  from  the  kidney  using  TriZol  Total  RNA  isolation  reagent 
according to standard procedures (Gibco BRL, Breda, The Netherlands). The obtained RNA 
was subjected to DNase treatment (Promega, Madison, WI, USA) to prevent genomic DNA 
contamination.  All  samples  were  resolved  on  1%  w/v  formaldehyde  agarose  gel  to 
evaluate  the  RNA  quality,  while  RNA  concentration  was  determined  by  measuring  the 
ratio  of  the  UV  absorbance  at  260  and  280  nm  using  the  NANODROP  2000c  (Thermo 
scientific,  Wilmington,  DE,  USA).  Thereafter,  1.5  µg  of  RNA  was  reverse  transcribed  by 





as  mRNA  levels  of  the  reference  gene  glyceraldehyde  3‐phosphate  dehydrogenase  
(GAPDH) as an endogenous control. Primer3 software (http://frodo.wi.mit.edu/primer3/) 







was  used  to  design  real‐time  quantitative  polymerase  chain  reaction  (qPCR)  primers 
according  to  the  general  criteria  for  real‐time  primers.  All  primer  sets  were  intron‐
overspanning, except for CLDN8, because this gene consists of only one exon. All primer 
sequences used  in this study are  listed  in Table 1. Prior to real‐time qPCR, the efficiency 
(95‐105%)  and  dynamic  range  (R2>0.98)  were  evaluated  for  each  primer  set.  Real‐time 
qPCRs were performed on a Bio‐Rad CFX96™ real‐time PCR and Bio‐Rad C1000™ Thermal 
Cycler  system.  Reactions  were  performed  in  duplicate  using  6.25  µL  of  SYBR®‐Green 
Master Mix (Applied Biosystems, Foster City, CA, USA), 12.5 ng of template cDNA and 400 
nM each primer in a final volume of 12.5 µL. All amplicons showed the correct sizes after 
gel  electrophoresis  and  the  dissociation  curves  showed  one  distinct  melting  peak, 
ensuring the absence of a non‐specific byproduct or primer dimers. Moreover, no reverse 
transcription  controls  and no  template  controls were  taken and  the difference between 
















dehydrogenase;  TRPM6,  transient  receptor  potential  melastatin  member  6;  NCC,  Na+,  Cl‐ 
cotransporter; TRPV5, transient receptor potential vanilloid member 5; Calbindin‐D28K, Ca
2+‐binding 
protein  D28K;  PV,  parvalbumin;  CLDN7,  claudin‐7;  CLDN8,  claudin‐8;





Immunohistochemical  staining  was  performed  on  7‐µm  cryosections  PLP‐fixed  kidney 
samples. Sections were stained with guinea pig anti‐TRPV5 (25), rabbit anti–calbindin‐D28K 
(Swant, Bellinzona, Switzerland) and rabbit anti‐NCC (26), as described previously (27, 28). 
Images  representing  the  entire  kidney  cortex  were  made  using  a  Zeiss  fluorescence 
microscope (Sliedrecht, the Netherlands) equipped with an AxioCam digital photo camera. 
For  semi‐quantitative  determination  of  protein  levels  as  the mean  of  integrated  optical 










Kidneys  of  control  and  furosemide‐treated  mice  were  homogenized  in  homogenization 
buffer  A  (HbA;  20  mmol/L  Tris/HCl  (pH  =  7.4),  5  mmol/L  MgCl2,  5  mmol/L  NaH2PO4,  1 
mmol/L  EDTA,  80  mmol/L  sucrose,  1  mmol/L  PMSF,  1  µg/mL  leupeptin  and  10  µg/mL 
pepstatin). Protein concentration of the homogenates was determined using the Bio‐Rad 
Protein  Assay  (Bio‐Rad,  Munich,  Germany).  The  proteins  were  solubilized  by  30’ 
incubation  at  37°C  in  Laemmli  buffer.  Sixty  micrograms  of  each  protein  sample  were 
separated  on  an  SDS‐PAGE  gel  and  blotted  to  a  PVDF‐nitrocellulose  membrane 
(Immobilon‐P, Millipore  Corporation,  Bedford, MA, USA).  Blots were  incubated  for  16  h 
with either a rabbit NCC antibody (1:500 dilution; Millipore, Billerica, MA, USA), a  rabbit 
anti–calbindin‐D28K (1:10 000 dilution; Swant, Bellinzona, Switzerland), a rabbit anti‐αENaC 
antibody  (1:1000  dilution;  StressMarq,  Victoria,  Canada)  or  a  mouse  tubulin  antibody 
(1:20 000 dilution; Invitrogen, Camarillo, CA, USA). Thereafter, blots were incubated with 
peroxidase‐conjugated  secondary  antibodies  after  which  proteins  were  visualized  by 
chemiluminescence (Pierce, Rockford, IL, USA). Immunopositive bands were scanned using 
ChemiDoc XRS (Bio‐Rad) and signals were analysed with the Quantity One software (Bio‐
Rad).  The  amount  of  NCC,  calbindin‐D28K  and  ENaC  protein  was  normalized  for  the 
corresponding total amount of protein, using tubulin protein levels or Coomassie staining. 




Data  are  expressed  as mean ±  SEM.  Statistical  analyses were performed by  Student’s  t‐







Ten‐week‐old  C57Bl/6J  mice  were  administered  furosemide  or  vehicle  using  osmotic 
minipumps for 7 days. Before and after the treatment the mice were individually housed 




determinations  showed  that  furosemide  treatment  resulted  in  substantially  increased 
levels of Na+ (158 ± 3 (furosemide) and 147 ± 1 mmol/L (control), P < 0.01) whereas serum 
Ca2+, Mg2+  and K+  values were not  significantly  altered  in mice  treated with  furosemide. 
Moreover,  furosemide  treatment  did  not  affect  the  urinary  Mg2+,  Ca2+,  Na+  and  K+ 
excretion  (µmol/24h).  Body  weight,  food  intake,  water  intake  and  production  of  feces 
were not significantly influenced by the chronic furosemide treatment. 
 


























The  effect  of  furosemide  treatment  on  the  renal  expression  level  of  TRPM6  was 
determined  by  real‐time  qPCR.  A  significant  increase  in  renal  TRPM6 mRNA  expression 




Figure  1.  Effect  of  chronic  furosemide 
treatment  on  renal  TRPM6  mRNA 
expression  level.  Real‐time  qPCR  was 
used  to  determine  the  epithelial  Mg2+ 
channel TRPM6 mRNA expression  level  in 
the  kidneys  of  mice  chronically  treated 
with  furosemide  (30  mg/kg/day  for  7 
days).  Expression  levels  are  corrected  for 



























































































































 Control  Furosemide
Next,  the  renal mRNA  expression  level  and  protein  abundance  of  the  thiazide‐sensitive 
NCC were determined. Chronic furosemide treatment had no effect on mRNA expression 
of NCC (98 ± 4% and 100 ± 5%, furosemide versus control, P > 0.2) (Figure 2A). The renal 
protein  abundance  of  NCC was  examined  by  IHC.  In  order  to  semi‐quantify  the  protein 








To  determine  the  specificity  of  the  upregulation  of  TRPM6  and  NCC  in  response  to 
furosemide treatment, renal mRNA expression levels of other genes specifically expressed 
in  the DCT and CNT were quantified. To evaluate the effect of  furosemide treatment on 
Ca2+  handling,  renal  expression  levels  of  TRPV5  and  the  cytosolic  Ca2+‐binding  protein 
calbindin‐D28K  in the late DCT (DCT2) and CNT were determined. Furosemide significantly 
increased the mRNA expression levels of TRPV5 (125 ± 6 and 100 ± 6%, furosemide versus 
control,  P  <  0.01)  (Figure  3A)  and  calbindin‐D28K  (153  ±  14  and  100  ±  10%,  furosemide 
versus control, P < 0.01) (Figure 3B). 
 







determined  by  computerized  analysis  of 















±  8%,  furosemide  versus  control,  P  <  0.01)  (Figure  3D)  were  markedly  increased. 
Subsequently,  the mRNA abundance of parvalbumin  (PV), a DCT‐specific Ca2+‐ and Mg2+‐
binding protein (29), the tight junction proteins claudin‐7 (CLDN7) and claudin‐8 (CLDN8) 







expressed  along  the  entire  aldosterone‐sensitive  part  of  the  nephron  (30)  and  the 











Figure  3.  Effect  of  chronic  furosemide  treatment  on  renal  TRPV5  and  calbindin‐D28K  expression 
levels. Real‐time  qPCR was  used  to  determine  the mRNA  expression  levels  of  the  epithelial  Ca2+ 
channel TRPV5  (A)  and  the cytosolic Ca2+‐binding protein  calbindin‐D28K  (B)  in  the kidneys of mice 
chronically  treated with  furosemide (30 mg/kg/day for 7 days). Expression  levels are corrected for 








































































































































































































































































































































Ultimately,  to  confirm  our  data  obtained  by  real‐time  qPCR  and  IHC,  we  performed 
immunoblotting  for  NCC,  calbindin‐D28K  and αENaC.  Quantification  of  the  immunoblots 
revealed that NCC (165 ± 15 and 100 ± 10%, furosemide versus control, P < 0.01) (Figure 
5A)  and  calbindin‐D28K  (180  ±  23  and  100  ±  12%,  furosemide  versus  control,  P  <  0.01) 
































on  renal  PV,  CLDN7,  CLDN8,  ENaC  and  NHE3 
mRNA  expression  levels.  Real‐time  qPCR  was 
used  to  determine  mRNA  levels  of  parvalbumin 
(PV) (A), claudin‐7 (CLDN7) (B), claudin‐8 (CLDN8) 
(C), the epithelial Na+ channel (ENaC) (D) and the 
Na+, H+  exchanger 3  (NHE3)  (E)  in  the  kidneys of 
mice  chronically  treated  with  furosemide  (30 
mg/kg/day  for  7  days).  Expression  levels  are 
corrected  for  GAPDH  and  presented  as  relative 






















































































































































Figure 5. Effect of  chronic  furosemide  treatment on 
renal  NCC,  calbindin‐D28K  and  αENaC  protein 
expression  levels.  The  effect  of  furosemide  (30 
mg/kg/day for 7 days) on protein expression levels of 
the Na+‐Cl‐ cotransporter (NCC) (A), calbindin‐D28K (B) 
and  the  alpha‐subunit  of  the  epithelial  Na+  channel 
(αENaC)  (C),  determined  by  immunoblotting.  The 
upper  part  of  each  figure  shows  the  immunoblot, 
with on the left side the molecular mass (in kDa) and 
the  lower  parts  depict  the  expression  levels  as 
percentage  of  control.  Values  are  presented  as 
average  ±  SEM  (n  =  4),  while  experiments  are 







Our  study  demonstrated  that  chronic  furosemide  treatment  induces  a  robust  polyuria. 
This effect, which is well known for blocking NKCC2, is the consequence of a defect in the 
urinary  concentrating  process  due  to  diminished Na+,  K+  and  Cl‐  cotransport  in  the  TAL. 
Importantly, serum Na+ values were significantly increased, whereas serum Mg2+, Ca2+ and 
K+ levels remained constant. The renal excretion of these electrolytes was not affected by 
chronic  furosemide  administration.  Apparently,  the  abolished  reabsorption  in  the  TAL 
during chronic  furosemide  treatment  is  compensated by an enhanced  transport of Mg2+ 
















smaller,  and  therefore  not  significant,  compound  changes  in  faeces,  water  intake  and 
body  weight.  Consequently,  the  hypernatremia  probably  reflects  a  loss  of  water  in  the 
furosemide  group.  Importantly,  this  could  have  affected  the  other  electrolyte  levels  as 
well.  Likewise,  NCC‐deficient  mice  appear  almost  normal  since  no  hypokalemia  was 
observed  and  just  a  mild  form  of  Gitelman  syndrome  (GS)  (36).  This  latter  finding  is 
unanticipated as well and could  indicate that  in some cases the mouse is not an optimal 
model for the human situation. 
Our  study  demonstrated  increased mRNA  expression  level  of  TRPM6  in  response  to 
chronic furosemide treatment. This novel finding unraveled increased active reabsorption 
of  Mg2+  in  the  DCT  as  a  responsible  molecular  mechanism  for  the  compensation  of 
impaired  Mg2+  reabsorption  in  the  TAL.  The  upregulation  of  TRPM6  in  this  study 
demonstrates,  like  shown  before  during  dietary  Mg2+  deprivation  (37),  the  gatekeeper 
function of this channel in the maintenance of the Mg2+ balance. Studies on the effect of 
chronic  furosemide  application  on Mg2+  homeostasis  are  scarce.  A minor  but  significant 
drop  (0.95  +/‐  0.01  mmol/L  and  0.99  +/‐  0.01  mmol/L,  furosemide  versus  control, 
respectively) in plasma Mg2+ was found in rats treated with furosemide for several months 
(38). In healthy volunteers, oral administration of torasemide (an analogue of furosemide) 
for  3  weeks  did  not  modify  total  plasma  Mg2+,  plasma  ionized  Mg2+  or  the  free‐Mg2+ 
fraction  (39).  The  sufficient  intake  of  Mg2+  during  furosemide  treatment  seems  to  be 
fundamental to optimal compensation (9) and aberrations in Mg2+ balance probably occur 
only due to comorbidity (11, 12).  
NCC  facilitates  cotransport  of  Na+  and  Cl‐  into  DCT  cells.  Mutations  in  the  gene 
encoding  NCC  cause  GS,  a  salt‐losing  disorder  characterized  by  hypokalemic  metabolic 
alkalosis, hypomagnesemia and hypocalciuria (36, 40). Moreover, NCC‐deficient mice have 
a  similar  phenotype,  including  hypomagnesemia  (36,  40,  41).  This  indicates  the 
importance of NCC for Mg2+ homeostasis, although  it might be an  indirect effect since  it 




active  Ca2+  reabsorption  and  is  a  key  player  in  determining  the  final  urinary  Ca2+ 
concentration (42). TRPV5 and calbindin‐D28K were on mRNA as well as on the protein level 
substantially  upregulated,  which  suggests  that  like  Mg2+  transport  also  active  Ca2+ 
transport  in  the  distal  part  of  the  nephron  is  increased  upon  chronic  administration  of 
furosemide.  Our  results  are  consistent  with  the  results  of  Lee  et  al.  concerning  the 
compensatory  adaptation  of  Ca2+  reabsorption  mediated  by  an  increase  in  Ca2+ 
transporter  abundance  in  the  kidney  during  chronic  furosemide  treatment.  In  contrast 











Previous  studies  performed  in  rats  have  demonstrated  that  6‐8  days  of  continuous 
furosemide infusion causes hypertrophy of the DCT, CNT and principal cells of the CD (16, 
17).  Microperfusion  experiments  in  rats  have  shown  an  enhanced  capacity  for  Na+ 
reabsorption and K+ secretion by the DCT, CNT and  initial CD (ICD)  in  this adapted state. 
Furosemide  treatment  did  not  affect  the  length  of  these  tubule  segments,  but  the 




concentration  of  furosemide  used  in  the  former  study.  We  cannot  exclude  which 
part/percentage  of  the  compensated  reabsorption  observed  in  our  study  is  caused  by 
increased  cell  volume  of  the  DCT  and  CNT.  However,  our  results  suggest  that  specific 






for  1  month  did  not  significantly  increase  urinary  Na+  excretion  (14,  43).  Loon  et  al. 
showed that continued renal Na+ loss during furosemide treatment, also for 1 month and 
in patients,  could be prevented. This was mediated by  increased  renal Na+  reabsorption 
and by a decreased natriuretic response to furosemide (15). They explained their findings 
by the negative impact of both the rebound and the braking phenomena. In contrast with 
those  studies  where  they  used  once‐daily  injections,  we  used  osmotic  minipumps 
resulting  in continuous release of furosemide. Our procedure makes the occurrence of a 
rebound period very unlikely, and thus is the compensation probably exclusively mediated 
by  the  braking  phenomenon.  Remarkably,  an  experiment  in  rats  comparable  with  our 
study showed an almost seven times  increased urinary volume and four times  increased 
urinary Na+ excretion levels. Moreover, they observed increased levels of all thee subunits 
of  ENaC,  whereas  the  NCC  protein  levels  were  unchanged  upon  furosemide  treatment 
(44).  In many other studies,  furosemide has been shown to  increase the abundance and 
activity  of  NCC  (16,  45,  46).  Interestingly,  northern  blot  analysis  of  NCC  mRNA 
demonstrated  no  significant  effect  of  furosemide,  similar  to  our  real‐time  qPCR  results, 
indicating  that  NCC  is  specifically  regulated  on  the  protein  level  (46).  The  significantly 








reabsorption  in  the  PT  via  NHE3  as  shown  for  chronic  thiazide  treatment  (26)  or 








serves  to  control  extracellular  fluid  homeostasis,  via  the WNK‐SPAK/OSR1  pathway  (49, 
50).  
In summary,  this study showed that mice adapt  to chronic  furosemide treatment, by 
the  upregulation  of  transporters  distal  to  the  furosemide  target  segment,  including 
TRPM6,  NCC  and  TRPV5.  In  this  way,  urinary  wasting  of  especially  Mg2+  and  the 
subsequent development of hypomagnesemia  is prevented.  Extrapolating  these  findings 
to  patients  on  continuous  furosemide  treatment,  with  normal  kidney  function  and 
consuming  an  adequate  diet,  suggests  that  it  is  unlikely  that  they  develop 
hypomagnesemia.  Intriguing  remains  why  patients  with  mutations  in  CLDN16  and 
CLDN19,  tight  junction  proteins  located  in  the  TAL,  develop  hypomagnesemia  due  to 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Mutations  in  the  tight‐junction  gene 
claudin  19  (CLDN19)  are  associated  with 
















































Background. Magnesium  (Mg2+)  is  an  essential  electrolyte  with  important  physiological 
functions. Consequently, hypomagnesemia, an electrolyte disorder  frequently diagnosed 
in critically ill patients, can have life‐threatening consequences. The kidney plays a central 




expression  levels of Mg2+‐related genes were measured  to determine  their  sensitivity  to 
the dietary Mg2+ content. Subsequently, parvalbumin (PV) and the thiazide‐sensitive Na+, 
Cl‐  cotransporter  (NCC),  both  co‐expressed  in  the  distal  convoluted  tubule  (DCT)  with 
TRPM6,  were  further  analysed  at  the  protein  level  using  immunoblotting  and 
immunohistochemistry (IHC). 
Results. Serum and urine electrolyte measurements revealed that dietary Mg2+ restriction 
resulted  in  significant  reduction  of  serum  Mg2+  and  Ca2+  levels,  and  that  the  urinary 
excretion  of  these  ions was  also markedly  reduced, while  phosphate  (Pi)  excretion was 
significantly  increased.  In  addition,  the  serum  FGF23  level  was  markedly  increased, 
whereas Pi was not  significantly  changed  in  the Mg
2+‐restricted mouse  group.  The  renal 
abundance of hepatocyte nuclear  factor 1 homeobox B  (HNF1B) and  the epithelial Mg2+ 
channel  TRPM6  were  increased  in  response  to  dietary  Mg2+  restriction,  whereas  other 





since  TRPM6,  HNF1B,  PV  and  NCC  expression  levels  were  adjusted.  Moreover, 
















in  diverse  biochemical  and  physiological  processes,  especially  in  neuromuscular 
functioning  (1). The plasma Mg2+ concentration  represents 1% of  total body Mg2+ and  is 
regulated  by  the  concerted  action  of  intestinal  absorption,  storage  in  bone  and 
reabsorption by the kidney (2). Hypomagnesemia is one of the most frequent electrolyte 
disturbances diagnosed in ~10% of the hospitalized patients and can be as high as 65% in 
intensive  care  patients  (3,  4).  Symptoms  of  hypomagnesemia  frequently  involve 
neuromuscular  irritability,  such  as  tetany  and  seizures,  and  if  not  corrected  in  time, 
cardiac arrhythmias (5). 
The  kidney  is  the  unfailing  organ  for Mg2+  homeostasis  (6).  About  80%  of  the  total 
plasma  Mg2+  is  ultrafiltrated  through  the  glomerular  membrane,  of  which  90‐95%  is 
reabsorbed  in  consecutive  segments of  the nephron  (1). Most of  the Mg2+  reabsorption 
takes place  in  a passive paracellular manner  in  the proximal  tubules  (PTs)  and  the  thick 
ascending  limb  of  Henle’s  loop  (TAL)  (10‐30%  and  40‐70%  of  the  filtered  load, 
respectively).  This  transport  is  driven  by  a  favourable  concentration  gradient  for  Mg2+ 
conditional on the Na+‐driven net water reabsorption in PT (7), and by the lumen‐positive 
transepithelial  potential  in  TAL,  which  is  mainly  generated  by  the  Na+,  K+,  2Cl‐ 
cotransporter (NKCC2) (8). Approximately 5‐10% of the filtered load is reabsorbed by the 
distal  convoluted  tubule  (DCT),  where  fine‐tuning  of  Mg2+  reabsorption  occurs  via  an 
active  reabsorption  process  (2).  In  this  segment,  the  epithelial  Mg2+  channel  TRPM6  is 
conspicuously  localized along  the apical membrane,  facilitating Mg2+  influx  (9). After  the 
DCT, Mg2+ is not further reabsorbed and consequently around 1‐3% of the filtered Mg2+ is 
excreted in the urine (1). 
During  the  last  decade,  isolated  cases  of  hereditary  disorders  of  Mg2+  homeostasis 
have played a major role  in the  identification of magnesiotropic proteins  localized  in the 
kidney,  like  the  discovery  of  TRPM6  in  autosomal‐recessive  disorder  hypomagnesemia 
with secondary hypocalcemia (HSH) (10, 11). This resulted in the elucidation of additional 
genes  responsible  for  maintenance  of  Mg2+  balance,  including  the  Na+,  K+‐ATPase  γ‐
subunit,  a  protein  encoded  by  the  FXYD2  gene  (12);  the  hepatocyte  nuclear  factor  1 
homeobox  B  (HNF1B),  which  is  shown  to  regulate  the  transcription  of  FXYD2  (13);  the 
KCNJ10  gene  (14,  15),  encoding  the  inwardly  rectifying  K+  channel  4.1  (Kir4.1)  (16);  the 
epidermal  growth  factor  (EGF)  (17);  and  finally,  the KCNA1 gene,  encoding  the  voltage‐





dietary Mg2+  content  affected  the  renal  TRPM6  expression  on mRNA  as well  as  protein 
level (22). Alterations in the Mg2+ balance can also cause Ca2+ disturbances as a secondary 
adverse effect  (23).  Indeed, Groenestege et al.  showed  that dietary Mg2+  restriction not 
only  leads  to  renal Mg2+  conservation,  but  also  reduces  Ca2+ wasting  (22).  Furthermore, 
the disease HSH displays  a  close  interaction between Mg2+  and Ca2+ homeostasis.  It  has 








physiological  functions  (25).  The  Ca2+‐sensing  receptor  plays  a  central  role  in  the 
homeostasis of both divalent ions (26). 
The  aim  of  the  present  study  was  to  investigate  which  magnesiotropic  players  are 
affected  by  the  dietary  Mg2+  content.  Furthermore,  the  effect  on  other  electrolyte 
transporters present in the TRPM6‐expressing DCT segment was investigated. To this end, 
C57BL/6J mice were  fed a Mg2+‐deficient  (0.003% w/w Mg2+)  and  ‐enriched  (0.48% w/w 
Mg2+) diet and serum and urine electrolyte measurements were performed for Mg2+, Ca2+, 
Na+  and  K+.  In  addition,  real‐time  quantitative  polymerase  chain  reaction  (qPCR)  and 







C57BL/6J  male  mice  (10  weeks  of  age)  were  purchased  from  Harlan/CPB  (Zeist,  The 
Netherlands)  and  maintained  in  a  temperature‐controlled  and  12/12  h  light‐darkness 
room. To study the effect of dietary Mg2+, mice (n = 10 per group) were fed for 14 days a 
Mg2+‐deficient  (0.003% w/w)  diet  or  a Mg2+‐enriched  (0.48% w/w)  diet  (#TD.93106  and 
#TD.10531,  respectively,  Harlan‐Teklad  Madison,  WI,  USA).  Both  diets  contained  0.6% 
w/w  Ca2+,  0.45%  w/w  phosphorus  and  2200  IU/kg  vitamin  D.  The  diets  and  deionized 
drinking water were provided ad libitum. A diet containing 0.19% w/w Mg2+ is considered 
normal for rodents (22). Before the start of the experiment and on day 12, the mice were 
individually  housed  in  metabolic  cages  enabling  24  h  urine  collections  (mineral  oil  was 
used to prevent evaporation) and to measure their water and food intake. At the end of 
the experiment, blood samples were  taken under  isoflurane  (3.5% v/v) anaesthesia, and 
the mice  were  sacrificed  by  cervical  dislocation.  Subsequently,  kidneys  and  colon  were 
immediately  frozen  in  liquid  nitrogen  for  RNA  and  protein  isolation  or  incubated  in 
periodate‐lysine‐paraformaldehyde (PLP)‐solution for IHC analysis. Blood was led to clot at 
room temperature, incubated overnight at 4°C and spun down for 5’ at 13 250 × g and the 









the  phosphomolybdate  method  with  an  Aeroset  analyser  (Abbott  Diagnostics,  Abbott 
Park,  IL,  USA).  Serum  FGF23  levels  were  determined  using  an  enzyme‐linked 
immunosorbent assay kit (Immutopics, San Clemente, CA, USA). 
 








Total  RNA  was  extracted  from  the  kidney  and  colon  using  TriZol  Total  RNA  isolation 
reagent  according  to  standard  procedures  (Gibco  BRL,  Breda,  The  Netherlands).  The 
obtained RNA was subjected to DNase treatment (Promega, Madison, WI, USA) to prevent 
genomic DNA  contamination.  To determine RNA  integrity,  all  samples were  resolved on 
ethidium bromide gel 1% w/v formaldehyde agarose gel, while RNA concentrations were 
determined by measuring  the  ratio of  the UV absorbance  at  260  and 280 nm using  the 
NANODROP  2000c  (Thermo  scientific,  Wilmington,  DE,  USA).  Next,  1.5  µg  of  RNA  was 
reverse transcribed by Molony‐Murine Leukemia Virus‐Reverse Transcriptase (Invitrogen, 





as  mRNA  levels  of  the  reference  gene  glyceraldehyde  3‐phosphate  dehydrogenase 
(GAPDH) as an endogenous control. Primer3 software (http://frodo.wi.mit.edu/primer3/) 
was  used  to  design  real‐time  qPCR  primers  according  to  the  general  criteria  for  these 
primers. All  primer  sequences used  in  this  study are  listed  in Table 1.  Prior  to  real‐time 





correct  sizes  after  gel  electrophoresis  and  the  dissociation  curves  showed  one  distinct 




IHC  was  performed  as  previously  described  (28).  Briefly,  immunohistochemical  staining 
was executed on 7 µm cryosections PLP‐fixed kidney samples. Sections were incubated for 
16 h at 4°C with the primary antibodies: rabbit anti‐parvalbumin (PV) antibody (1:200; PV‐
28,  Swant,  Bellinzona,  Switzerland),  guinea  pig  anti‐TRPV5  (1:2000)  (29),  rabbit  anti‐
calbindin‐D28K (1:300; Swant), and rabbit anti‐NCC (1:100) (30). For detection, the sections 
were  incubated  with  Alexa‐conjugated  secondary  antibodies.  Images  representing  the 
entire  kidney  cortex  were made  using  a  Zeiss  fluorescence microscope  (Sliedrecht,  The 
Netherlands)  equipped  with  an  AxioCam  digital  photo  camera.  For  semi‐quantitative 






mM  PMSF,  1  µg/mL  leupeptin  and  10  µg/mL  pepstatin).  Protein  concentration  of  the 
homogenates was determined by Bio‐Rad Protein Assay (Bio‐Rad, Munich, Germany). The 
proteins were solubilized by 30’  incubation at 37°C  in Laemmli buffer. 60 micrograms of 




































dehydrogenase;  TRPM6,  transient  receptor  potential  melastatin  member  6;  TRPM7,  transient 
receptor potential melastatin member 7; Kv1.1, voltage‐gated K+ channel, shaker, member 1.1; EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor; Kir4.1, inwardly rectifying K+ (Kir) 










Student’s  t‐test.  The  low Mg2+  diet mouse  group was  compared with  the high Mg2+  diet 
mouse group. P < 0.05 was considered statistically significant. All analyses were performed 

























Serum       
   [Mg2+] (mmol/L)  0.63 ± 0.04b  1.80 ± 0.04  1.6‐1.8 
   [Ca2+] (mmol/L)  1.94 ± 0.02b  2.06 ± 0.02  2.2‐2.4 
   [Na+] (mmol/L)  139.6 ± 0.8a  136.2 ± 0.5  130‐150 
   [K+] (mmol/L)  7.60 ± 0.07a  7.93 ± 0.09  6‐8 
   [Pi] (mmol/L)  2.4 ± 0.2  2.0 ± 0.1  2.2‐2.7 
   [FGF23] (pg/mL)  157 ±19b  64 ± 8  60‐140 
Urine       
   Volume (mL/24h)  1.3 ± 0.1  1.2 ± 0.1  ~1.0 
   Mg2+ excretion (µmol/24h)  0.22 ± 0.04b  139 ±12  ~30 
   Ca2+ excretion (µmol/24h)  0.9 ± 0.2b  23 ± 2  ~7.0 
   Na+ excretion (µmol/24h)  91 ± 6  76 ± 9  ~100 
   K+ excretion (µmol/24h)  166 ± 6  154 ± 10  ~200 
   Pi excretion (µmol/24h)  79 ± 8
b  1.9 ± 0.3  ~2.8 
0.003%  w/w Mg2+,  mice  receiving  the  deficient  (0.003%  w/w) Mg2+  diet;  0.48%  w/w Mg2+,  mice 








accompanied  by  a  marked  hypocalcemia  compared  with  the  mice  receiving  a  Mg2+‐
enriched diet. Moreover, serum Na+ and K+ were slightly, but significantly affected by the 







changed  in  the  Mg2+‐restricted  mouse  group.  Dietary  Mg2+  restriction  resulted  in  a 
substantial decreased urinary Mg2+ and Ca2+ excretion, whereas the Na+ and K+ excretions 
were not affected. Further, the urinary Pi excretion was markedly increased in the mouse 
group  fed with  the  low Mg2+ diet  (Table 2).  Body weight,  food  intake, water  intake and 





ubiquitously  expressed  Mg2+  channel  TRPM7,  Kv1.1,  EGF,  EGF  receptor  (EGFR),  Kir4.1, 
HNF1B, FXYD domain‐containing ion transport regulator 2, splice variants a and b (FXYD2a 

















homeostasis  in  total  kidney  lysate of mice on  a Mg2+‐deficient  diet  (0.003% w/w),  or  an  enriched 
Mg2+  diet  (0.48%  w/w).  Expression  levels  are  corrected  for  GAPDH  and  presented  as  a  relative 









Interestingly,  dietary  Mg2+  restriction  markedly  upregulated  the  HNF1B  level.  However, 
differences  in  dietary  Mg2+  content  did  not  significantly  affect  the  renal  abundance  of 
TRPM7,  Kv1.1,  EGF,  EGFR,  Kir4.1,  Fxyd2a,  Fxyd2b,  CLDN16  or  CLDN19.  Next,  HNF1B 
protein  levels  of  kidneys  of  the  various  dietary  regimens were  determined.  In  addition, 



























































































































































































































































































 0.003% Mg2+  0.48% Mg2+





















































+,  H+  exchanger  3  (NHE3)  and  the  epithelial  Na
+  channel  (ENaC)  were 










epithelial Na+ channel  (ENaC)  (D)  in kidneys of mice fed a Mg2+‐deficient diet  (0.003% w/w), or an 
enriched Mg2+  diet  (0.48%  w/w).  Expression  levels  are  corrected  for  GAPDH  and  presented  as  a 
relative percentage of expression  in mice on  the high Mg2+ diet. TRPV5 and calbindin‐D28K protein 







In  contrast,  the  mRNA  levels  of  NHE3  and  ENaC  were  not  significantly  affected  by  the 
dietary Mg2+ content (93 ± 6 and 100 ± 7% for NHE3 and 99 ± 7 and 100 ± 4% for ENaC for 
low  versus  high  Mg2+  diet,  respectively,  P  >  0.05).  Next,  the  renal  protein  levels  were 





































































































































































































































































accompanied  by  hypocalcemia.  Moreover,  the  serum  Na+:K+  ratio  was  slightly  but 
significantly  increased  under  dietary  Mg2+  restriction.  As  renal  adaptive  response,  the 
urinary  excretion  of  Mg2+  as  well  as  Ca2+  was  markedly  reduced  in  these  mice. 
Interestingly,  the  urinary  level  of  Pi  was  regulated  in  opposite  direction  compared with 
Ca2+  and  also  serum  FGF23  was  increased  in  the  Mg2+‐restricted  mice.  Analysis  of 
expression  levels  revealed  that  the  dietary  Mg2+  content  regulated  TRPM6  and  HNF1B 
abundance, while  the other magnesiotropic  transporters were not  affected.  In  addition, 
the expression of TRPV5 and calbindin‐D28K was markedly lower in the Mg
2+‐restricted diet 
compared  with  the  enriched  Mg2+  diet.  Finally,  renal  PV  was  upregulated  and  NCC 
downregulated  as  a  consequence  of  the  low  Mg2+  diet.  These  results  clearly  indicate 
profound  effects  of Mg2+  restriction  on  gene  expression  levels  in  the  distal  part  of  the 
nephron. The hypomagnesemia and hypomagnesuria  confirmed  that  the 2‐week dietary 
Mg2+ restriction was effective. Furthermore, we revealed that the mRNA level of TRPM6 in 
kidney  as well  as  in  colon was  upregulated  during Mg2+  restriction.  This  suggests  that  a 
diminished Mg2+ excretion in kidney is accompanied by an enhanced absorption of Mg2+ in 
the  large  intestine.  Whether  the  direct  trigger  for  TRPM6  upregulation  during  a 
hypomagnesemic  state  is  intrinsic  (sensing  of  Mg2+  concentration  by  TRPM6  itself)  or 
external  (like  hormonal  regulation)  remains  elusive.  Interestingly,  the  other 
magnesiotropic genes tested (TRPM7, Kv1.1, EGF, EGFR, Kir4.1, FXYD2a, FXYD2b, CLDN16 
and  CLDN19)  were  not  affected  by  the  amount  of  dietary  Mg2+  intake.  Although,  we 
cannot  exclude  changes  on  protein  level  of  these  players,  these  results  emphasize  the 
physiologic importance of TRPM6, as a gatekeeper in Mg2+ balance. In our previous dietary 
studies, we did not observe a reduced serum Ca2+ level nor an increased level of TRPM6 in 
colon  during  Mg2+  restriction  (22).  This  difference  can  be  due  to  the  extended  dietary 
period or to the more severe Mg2+ restriction in the current study. In addition, our data on 
TRPM6 regulation in kidney and colon are in line with the study of Rondon et al. (31). 
HNF1B  plays  an  essential  role  during  renal  embryonic  development.  Besides,  it  has 
been  shown  to  be  particularly  important  for  the maintenance  of Mg2+  and  Ca2+  balance 
once  maturated,  since  mutations  in  HNF1B  caused  hypomagnesemia  and  hypocalciuria 
(13).  The  upregulation  of  HNF1B  during  dietary Mg2+  restriction  is,  therefore,  of  special 
interest. HNF1B regulates the transcription of FXYD2 (32), which encodes the γ‐subunit of 
the Na+, K+‐ATPase. This  latter  transmembrane protein has been shown to be  important 
for maintainance of Na+, K+‐ATPase capacity  (33). Probably,  impaired capacity  to  set  the 
basolateral  membrane  potential,  which  ultimately  hinders  reabsorption  of  Mg2+  via 
TRPM6,  seems  to  be  the  mechanism  by  which  decreased  expression  of  the  γ‐subunit 
resulted  in  hypomagnesemia  (32,  34).  However,  the  expression  level  of  both  FXYD2 
transcription  variants  remained  constant  during  the Mg2+  restriction.  This  suggests  that 







HNF1B  needs  a  co‐factor  to  promote  transcription  of  the  γa‐subunit  or  that  HNF1B  is 
responsible for maintaining the Mg2+ balance by other means.  
The  effect  of  dietary  Mg2+  restriction  is  not  limited  to  Mg2+  homeostasis  since  it 
seriously  affected  the  renal  handling  of  Ca2+  as  well  as  of  Pi.  Pi  is  required  for  cellular 
functions and skeletal mineralization (35), and its homeostasis is closely related to that of 
Ca2+ (36). The combination of a trend for increased serum Pi, significantly increased serum 
FGF23  and  increased  urinary  Pi  excretion,  suggest  profound  effects  of  dietary  Mg
2+ 




hypoparathyroidism  and  consequently  hypocalcemia  in  combination  with 
hyperphosphatemia (39, 40), is in line with our data. 
Hypomagnesemia  in  patients  is  frequently  accompanied  by  hypocalciuria  when  the 
NCC activity  is also diminished,  i.e. Gitelman syndrome (GS) or chronic thiazide use (41). 
Increased passive Ca2+ reabsorption in the PT, accompanied by an increased level of NHE3, 
responsible  for Na+ and subsequent paracellular Ca2+  reabsorption  (42), accounts  for  the 
underlying  mechanism  (43).  This  is  implicated  via  extracellular  volume  contraction  and 
activation  of  the  renin‐angiotensin‐aldosterone  system  (RAAS)  (43).  In  our  study,  the 
mRNA  expression  level  of NHE3 was  not  affected  by  dietary Mg2+  intake, which  implies 
that Ca2+ reabsorption in PT was not increased. Since, angiotensin II is a direct stimulator 
of  ENaC  activity  (44),  our  observation  that  ENaC mRNA  level was  not  regulated  further 
supports  that  RAAS  signaling  is  not  activated. However,  this  finding  also  implicates  that 
the causative factor for the Na:K imbalances, remains elusive.  
The  significant  downregulation  of  TRPV5  and  calbindin‐D28K,  for  which  localization  is 
restricted to DCT and connecting tubules (CNT), indicates that active Ca2+ reabsorption in 
these  tubule  segments  is  decreased.  This  could  be  the  consequence  of  increased 
reabsorption  of  Ca2+  in  TAL.  Here,  Ca2+  and  Mg2+  transport  compete  for  the  same 
paracellular  route.  Given  the  hypomagnesemia,  a  more  favourable  situation  is  possibly 
created to reabsorb Ca2+ in TAL (45). Van Abel et al. showed that the TRPV5 and calbindin‐
D28K  expression  levels  are  dependent  on  PTH  stimulation  (46).  The  reduced  TRPV5  and 
calbindin‐D28K levels as measured in the present study indicate a defect in the regulation of 
these proteins  by  PTH.  Subsequently,  the  co‐existence of  hypocalciuria  and  a decreased 
serum Ca2+ level in the low Mg2+ diet group suggests a disturbed bone metabolism. This is 
possibly  induced  by  end‐organ  resistance  to  PTH  also  known  as 
pseudohypoparathyroidism  (47).  The  latter, mediated by  the  continuously high  levels of 
PTH, induced by the Mg2+‐deficient state (48). Disturbances in enzyme activity might form 
the underlying mechanism for the secondary effects on Ca2+ balance. Probably, defects in 
PTH  secretion only  occur  after more prolonged periods of Mg2+  deficiency  (49),  like  the 
experimental period of 2 weeks used in this study. 
To  obtain  more  insight  into  the  function  of  DCT  during  hypomagnesemia,  the 











PV  knockout  mice  showed  polyuria  and  some  aberrations  in  electrolyte  homeostasis, 
however,  not  for Mg2+  (51).  Interestingly,  Belge et al.  (51) observed  reduced expression 
levels of NCC in the PV knockout mice, possibly mediated by diminished capacity to buffer 
intracellular Ca2+. NCC forms the apical entry mechanism for Na+ and Cl‐ in DCT. Mutations 
in  the  NCC  gene  cause  GS,  a  salt‐wasting  renal  disorder  characterized  by  hypokalemia, 
metabolic alkalosis, hypomagnesemia and hypocalciuria (52). Besides, NCC‐deficient mice 
have  a  similar  phenotype,  including  hypomagnesemia  (53).  This  suggests  that  NCC  is 
important for the maintenance of the Mg2+ balance. Interestingly, our data displayed that 









Figure  5  presents  the  main  results  of  the  present  study  and  a  schematic  model  of 
adaptations  in  the  nephron  in  response  to  dietary Mg2+  restriction.  In  short,  this  study 
revealed  that  HNF1B  and  TRPM6  act  as  unique  regulators  of  Mg2+  homeostasis.  In 






FGF23  level  and  increased  urinary  Pi  excretion  in  Mg
2+‐restricted  mice  suggests 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middle  of  this  figure,  the  functional  unit  of  the  kidney,  the  nephron  is  shown.  The  different 
segments  affected  by  dietary Mg2+  restriction  are  indicated  in  this  nephron  and  enlarged  cells  of 
these respective segments surround the nephron.  In TAL, passive reabsorption of Ca2+  is  increased 
due  to  lack  of  competition  of Mg2+  ions.  CLDN16  and  CLDN19 mRNA  expression  levels  were  not 
affected. In DCT1, TRPM6 mRNA and HNF1B mRNA and protein expression levels are increased. The 
detailed  physiological  relevance  of  HNF1B  concerning  Mg2+  balance  is  still  unknown.  HNF1B 
probably  plays  an  important  role  in  the  stabilization  of  the  Na+,  K+‐ATPase  in  the  basolateral 
membrane. In addition, NCC is downregulated and PV is upregulated. We hypothesize that this is to 
counteract  increased  [Ca2+]i,  which  in  turn  is  the  consequence  of  release  of  Ca
2+  from  the  ER  or 
mitochondria, triggered by a decreased [Mg2+]i level. Alternatively, the presumed lower [Mg
2+]i level, 
resulting  from  the  dietary Mg2+  restriction,  possibly  exerts more  direct  effects  on  these  proteins. 
More  distal  in  the  CNT,  TRPV5  and  calbindin‐D28K  are  downregulated;  however,  the  underlying 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Background.  Magnesium  (Mg2+)  is  essential  for  many  functions  in  our  body  and  the 
plasma Mg2+  concentration  is  tightly  regulated.  The  identification  of  a  mutation  in  the 
epidermal growth factor (EGF) gene in two sisters with isolated autosomal recessive renal 
hypomagnesemia  (IRH),  linked  this  hormone  to  Mg2+  homeostasis.  This  homozygous 
P1070L mutation in precursor EGF (pro‐EGF) specifically prevents secretion of pro‐EGF to 
the  basolateral  side  in  polarized  Madin‐Darby  canine  kidney  (MDCK)  cells.  As  a 
consequence of this mutation, the renal EGF receptor (EGFR) is not adequately activated, 
resulting  in  impaired  stimulation  of  the  epithelial  Mg2+  channel  TRPM6  and  thereby 




lines.  The  membrane  fraction  was  studied  using  cell  surface  biotinylation  and 
immunoblotting  techniques.  The  different  cleavage  products  of  pro‐EGF  in  the  secreted 
fraction were separated into two fractions, one containing the 3‐50 kD (pro)‐EGF products 
and a fraction containing pro‐EGF proteins larger than 50 kD, concentrated and analysed 
by  enzyme‐linked  immunosorbent  assay  (ELISA)  and  immunoblotting.  In  addition, 
subcellular  localization of wild‐type pro‐EGF‐GFP  (pro‐EGF‐WT)  and pro‐EGF‐P1070L‐GFP 
(pro‐EGF‐P1070L) was determined by immunocytochemistry and confocal microscopy.   
Results.  Immunocytochemical  detection  of  the  extracellular  EGF‐epitope  revealed  that 
pro‐EGF‐WT  and  pro‐EGF‐P1070L  are  both  predominantly  present  on  the  apical 
membrane. Moreover,  immunoblotting  and ELISA experiments of  the  secreted  (pro)EGF 
fractions  showed  that  this  protein  is  mainly  secreted  to  the  apical  side  of  the  cell  and 
processed  into mature  EGF.  Impaired  secretion  of  the mutant, which  affected  both  the 
apical  and  basolateral  compartment,  was  demonstrated.  In  addition,  our  data  revealed 
that  the abundance of EGF  in  the apical 3‐50 kD  fraction was  three‐four  times higher  in 
MDCKI cells and similar in MDCKII cells, to the amount of (pro‐)EGF in the > 50 kD fraction. 
In contrast, at the basolateral side the EGF abundance was two‐six times lower in the 3‐50 
kD  fraction  when  compared  with  the  >  50  kD  fraction.  Finally,  addition  of  the 
metalloprotease inhibitor phenanthroline did not affect the secretion of pro‐EGF.  
Conclusions. Pro‐EGF‐WT and pro‐EGF‐P1070L are principally sorted to the apical side of 
MDCK  cells  and  secreted  and  processed  into  the  apical  medium.  The  P1070L mutation 
likely results in impaired secretion of pro‐EGF and consequently inadequate stimulation of 
the  EGFR.  This  results  in  a  physiological  defect  at  the  basolateral  side  due  to  the  lower 











Magnesium  (Mg2+) plays a  critical  role  in many biochemical  and physiological processes, 
including  DNA  synthesis,  neurotransmission,  and  hormone  receptor  binding  (1).  The 
plasma Mg2+ concentration  is maintained within a narrow range by adapting  the urinary 
Mg2+  excretion  in  response  to  altered  absorption  by  the  intestine  (2).  However, 
hypomagnesemia (plasma Mg2+ < 0.7 mmol/L) is a frequent problem, observed in ∼10% of 
the general population and can affect up to 65% of  intensive care patients  (3). This  is of 
special  interest  given  the  correlation  between  hypomagnesemia  and  common  chronic 
diseases  such  as  diabetes  and  cardiac  disturbances  (4,  5).  Although  hypomagnesemia  is 
often  asymptomatic,  patients  may  suffer  from  neuromuscular,  cardiovascular  and 
metabolic disturbances like tremor, convolutions and cardiac arrhythmias (6).  
One important aspect of Mg2+ homeostasis is the transcellular Mg2+ transport through 
the  TRPM6  channel,  which  is  predominantly  expressed  in  the  distal  convoluted  tubule 
(DCT)  of  the  kidney  and  in  the  distal  part  of  the  intestine  (7,  8).    Recently,  our  group 
identified  a  homozygous mutation  (P1070L)  in  the  epidermal  growth  factor  (EGF)  gene, 
encoding precursor EGF  (pro‐EGF)  in  two sisters with  isolated autosomal  recessive  renal 
hypomagnesemia  (IRH)  (9).  Moreover,  this  study  revealed  that  activation  of  the  EGF 
receptor  (EGFR),  located  at  the  basolateral  membrane  of  DCT  cells  (10),  by  EGF  is  the 
essential  upstream  point  towards  TRPM6  activation  (9).  Follow‐up  experiments 
demonstrated  that EGFR‐mediated  stimulation of TRPM6  is affected by  redistribution of 
vesicular  TRPM6  and  its  insertion  into  the  apical  plasma membrane  (11).  Other  studies 
reported  that patients develop hypomagnesemia when treated with an EGFR antagonist 
(cetuximab) (12‐15). EGFR  is a useful target  in chemotherapy since this receptor  is often 
upregulated  in  solid  tumours,  and  EGFR  participates  in  signaling  cascades  that  are 
disturbed in cancer cells (16). 
EGF  is  known  for  its  growth‐promoting  effects  on  epithelial  cells  and  it  has  been 
demonstrated to be an effective inhibitor of gastric acid and pepsin secretion (17). In the 
kidney,  EGF  also  affects  the  glomerular  filtration  and  it  decreases  the  activity  of  the 
epithelial Na+ channel (ENaC) (18, 19). Renal EGF expression is localized to the apical side 
of  the DCT and  the  thick  ascending  limb of Henle’s  loop  (TAL)  (9,  20).  EGF  is  principally 
synthesized by the kidney (21), and secreted and maturated in large amounts in the urine 
(22,  23).  Groenestege  et  al.  showed  that  the  P1070L  mutation  in  pro‐EGF  specifically 
prevents secretion of this protein to the basolateral side in polarized MDCKI cells (9). As a 
consequence  of  this  mutation,  the  renal  EGFR  is  inadequately  activated,  resulting  in 
impaired  stimulation  of  TRPM6,  and  thereby  causing  renal  Mg2+  loss.  The  aberrant 




soluble  pro‐EGF  of  170  kD,  which  is  further  processed  into  a  45‐70  kD  pro‐EGF 
intermediate,  to  finally  generate  the  6  kD  mature  peptide  hormone  EGF  (25,  26). 
Measurements  of  EGF  in  urine  and  other  bodily  fluids,  using  different  approaches, 
confirmed the presence of these different forms of (pro‐)EGF in vivo (23, 25, 27, 28). 







cleavage  of  the  large  precursor  protein  (29,  30).  The  proline  affected  by  the  mutation 
represents  the  second  proline  of  the  basolateral‐sorting  motif  PXXP  (with  X  being  an 
arbitrary amino acid) (9, 31). This indicated that the P1070L mutation in the carboxyl‐tail 
of pro‐EGF might  result  in  impaired sorting of  the protein  to  the basolateral membrane. 
Alternatively, cleavage of the mutated protein at the basolateral side can cause impaired 




its  release  from  the  plasma  membrane  is  probably  executed  by  ADAM10,  whereas 
ADAM17  is  responsible  for  processing  of  other  EGFR  ligands  (35,  36).  The  regulation  of 
ADAM10  remains  elusive;  however,  it  might  be  that  shedding  can  be  stimulated  by 
phorbol  esters  like phorbol myristate  acetate  (PMA),  as  reported  for ADAM17  (34),  and 
decreased by metalloprotease inhibitors (36).  
The  main  objective  of  this  study  was  to  delineate  the  function  of  (pro‐)EGF  in  the 
molecular regulation of the renal Mg2+ handling. For this purpose MDCK cells were stably 
transfected  with  wild‐type  pro‐EGF  and  pro‐EGF‐P1070L  tagged  with  green  fluorescent 
protein (GFP) using the inducible T‐REx system. The sorting and processing of pro‐EGF and 
the mutant was analysed by detection of these proteins or cleavage products in different 







Full‐length  pro‐EGF  (pro‐EGF‐WT)  and  mutant  (P1070L)  pro‐EGF  both  tagged  with  GFP 
expressed  in  vector  plasmid  CB7  (pCB7)  (9)  were  cloned  into  the  inducible  expression 
plasmid (pcDNA4/TO/myc‐HisA) (gift of Dr. Nijtmans), using the KpnI and AgeI restriction 





Human  Embryonic  Kidney  293  (HEK293)  cells  were  seeded  at  a  density  of  3.0×106 
cells/petri  dish  in Dulbecco’s modified  Eagle’s medium  (DMEM)  (BioWhittaker,  Verviers, 
Belgium) supplemented with 10% (v/v) fetal calf serum (FCS) (PAA, Linz, Austria), 2 mM L‐
glutamine, 0.1 mM non‐essential amino acids (Invitrogen) and 10 ug/mL ciproxin at 37°C 
in a humidity‐controlled  incubator with 5%  (v/v) CO2  in air. The next day,  the cells were 
transiently  transfected with pro‐EGF‐WT‐GFP or pro‐EGF‐P1070L‐GFP  in  the pCB7 vector 
using polyethylenimine (PEI) (Brunschwig, Basel, Switzerland) with a DNA:PEI ratio of 1:6. 
Madin‐Darby  canine  kidney  type  I  (MDCKI)  and  II  (MDCKII)  cells  were  seeded  at  a 
density  of  1.5×105  cells/12‐well  in  DMEM  supplemented  with  5%  (v/v)  FCS,  2  mM  L‐
glutamine, 0.1 mM non‐essential amino acids (Invitrogen) and 10 ug/mL ciproxin at 37°C 
in  a  humidity‐controlled  incubator  with  5%  (v/v)  CO2  in  air.  They  were  transiently 
transfected  with  pro‐EGF‐WT‐GFP  or  pro‐EGF‐P1070L‐GFP  in  the  pCB7  vector  using  the 






of  1:2;    ii)  PEI  with  a  DNA:PEI  ratio  of  1:6;  ii)  Metafectene  Pro  (Biontex, 
Martinsried/Planegg, Germany) with a DNA:Metafectene Pro ratio of 1:3 and; iv) FuGENE 
HD  (Roche,  Penzberg,  Germany)  DNA:  FuGENE  HD  ratio  of  1:2.5.  The  percentage  of 
positive  cells  for  pro‐EGF  expression was  determined by  counting  the  “green”  cells  in  a 
representative area of cells, using fluorescent microscopy. 
For  transient  transfection  of  MDCKI  cells  using  T‐REx,  cells  were  seeded  on  petri  d                                                                                                                                                                                                                                                                                  
ishes (2.0×106 cells/dish) or on 6‐well plates (3.0×105 cells/well). The next day, these cells 
were  transiently  co‐transfected with  pcDNA6/TR  and pro‐EGF‐WT‐GFP,  pro‐EGF‐P1070L‐
GFP  or  the  empty  expression  vector,  using  the  pcDNA6/TR  plasmid  and  the  inducible 
expression  construct  at  a  ratio  of  6:1  (w:w)  and  FuGENE HD,  DNA:  FuGENE HD  ratio  of 
1:2.5. These cells were used for biotinylation or detection of pro‐EGF in the medium. 
For  the generation of stable expression of MDCKI and MDCKII cells, pro‐EGF‐WT‐GFP 
or  pro‐EGF‐P1070L‐GFP  in  the  pCB7  vector,  pro‐EGF‐WT‐GFP  or  pro‐EGF‐P1070L‐GFP  in 
the  pcDNA4/TO/myc‐HisA  plasmid  and  pcDNA6/TR were  transfected  using  the  calcium‐
phosphate method as previously described  (37).  In  short,  1.0×106  cells were plated  in  a 
petri dish. The next day, the cells were transfected using 25 µg of circular DNA, followed 
by  a  glycerol  shock  once  small  crystals  were  observed.  First,  transfection  with  the 
regulatory  plasmid pcDNA6/TR was performed,  using  5 µg/mL blasticidin  (Invitrogen)  as 
selection  medium.  Second,  these  cells  were  transfected  with  the  inducible  expression 
vector:  pcDNA4/TO/myc‐HisA  containing  pro‐EGF‐WT‐GFP  or  pro‐EGF‐P1070L‐GFP.  125 
µg/mL  Zeocin  (Invitrogen)  was  added  to  the  medium  for  selection  of  positive  co‐
transfected  inducible clones. 75 µg/mL hygromycin B  (Invitrogen) was used  to  select  for 
positive  clones  of  cells  transfected with  pro‐EGF‐WT‐GFP  or  pro‐EGF‐P1070L‐GFP  in  the 
pCB7  vector. Within  14  days  after  transfection,  individual  colonies were  selected  (using 
cloning rings) and expanded.  
For  experiments  on  semi‐permeable  filters  (Transwell®,  0.4  µm  pore  size,  Corning 
Costar, Cambridge, MA, USA), using the stably transfected MDCK cells, these exponentially 
growing cells were trypsinized and seeded at a density of 5.0×105 cells/6‐well and 1.5×105 
cells/12‐well.  The  6‐well  filters  were  used  for  immunoblotting  in  combination  with 
sampling of the medium and the 12‐well filters for immunocytochemistry. After 3‐5 days, 
depending  on  the  transcellular  resistance,  the  cells  were  induced  with  100  ng/mL 
doxycycline  (Sigma,  St  Louis,  MO,  USA)  for  24  h.  For  experiments  with  non‐polarized 
MDCKI  cells,  protein  expression  was  induced  the  day  after  transfection.  If  applied,  10 








We  determined whether  this  system was  useful  to  express  pro‐EGF‐GFP.  Therefore, 
PcDNA6/TR + pcDNA4/TO/myc‐HisA containing pro‐EGF‐WT‐GFP, pro‐EGF‐P1070L‐GFP or 









Figure  1.  Tetracycline‐Regulated  Expression  (T‐REx)  system.  Schematic  overview  of  the  different 
steps  necessary  for  creating  inducible  transcription  of  pro‐EGF‐WT‐GFP  and  pro‐EGF‐P1070L‐GFP, 
using  the  T‐REx  system.  Pro‐EGF‐WT‐GFP  and  pro‐EGF‐P1070L‐GFP  are  cloned  into  the  inducible 
expression vector and these constructs are co‐transfected with the regulatory plasmid, pcDNA6/TR, 
into  MDCKI  or  MDCKII  cells.  Subsequently,  cells  are  incubated  with  doxycycline  to  remove 
repression  of  the  promoter  and  induce  transcription  of  pro‐EGF‐GFP,  allowing  us  to  perform 




For  selection  of  stably‐transfected  MDCK  cells,  positive  clones  containing  the  TetR 
(pcDNA6/TR)  were  transiently  co‐transfected  with  pcDNA6/TO/Luciferase  and  induced 
with  doxycycline  (100  ng/mL)  or  not,  and  screened  using  the  Luciferase  Assay  System 
(Promega, Madison, WI, USA). The clones expressing the highest expression of TetR after 
induction with  doxycycline  and  the  lowest  basal  expression were  used  as  hosts  for  the 
inducible expression construct.  
To determine  the optimal amount of antibiotics needed  for our  system,  “kill  curves” 
were  made  (Figure  2).  For  this  purpose,  cells  were  seeded  in  6‐well  plates,  with  a 
confluency of approximately 25%. The antibiotics (0‐10 µg/mL blasticidin and 0‐250 µg/mL 
Zeocin) were  immediately  added    (i.e.  before  the  cells  were  attached  to  the well),  and 
replenished  every  3‐4  days.  Figure  2  showed  that  5  µg/mL  blasticidin  and  125  µg/mL 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and P1070L-GFP into the 
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MDCKI    (triangles)  and 
MDCKII  (circles)  clones 
expressing  the  transfected 
plasmids  and  for  continued 
culture  of  these  selected 










mM  PMSF,  1  μg/mL  pepstatin  A,  and  10  ng/mL  leupeptin).  Subsequently,  the  proteins 
collected in the FCS‐free culture media were separated and concentrated using the YM‐50 







5  mM  EDTA,  50  mM  Tris‐HCl  pH  7.5,  1%  (v/v)  NP‐40  and  protease  inhibitors  at  4°C, 
scraped from the filter or well and spun down for 10’ at 14 000 × g. Finally, biotinylated 




The  collected  proteins  from  the  cell  lysates  or media  were  denatured  by  incubation  in 
Laemmli/DTT  buffer  for  30’  at  37°C.  Each  protein  sample  (60  μg)  was  separated  using 
sodium dodecyl  sulfate  polyacrylamide  gel  electrophoresis  (SDS–PAGE)  and blotted  to  a 
PVDF‐nitrocellulose membrane  (Immobilon‐P, Millipore).  Blots  were  incubated  for  16  h 






anti‐EGF  (1:1000 dilution;  Ab‐3,  Calbiochem, Millipore),  or mouse  anti‐β‐actin  (1:10  000 
dilution; Sigma) antibody,  in Tris‐Buffered Saline Tween‐20 (TBS‐T) pH 7.6 supplemented 
with 1% w/v non‐fat dried milk. Blots were incubated for 1 h with 1:5000 diluted goat anti‐
rabbit  IgG’s  or  1:2000  diluted  goat  anti‐mouse  IgG’s  (Sigma)  as  secondary  antibodies 
coupled  to  horseradish  peroxidase.  Proteins  were  visualized  using  enhanced 
chemiluminescence  (Pierce).  Immunopositive  bands  were  scanned  using  ChemiDoc  XRS 
(Bio‐Rad)  and  signals  were  analysed  with  the  Quantity  One  software  (Bio‐Rad).  The 











cells  were  permeabilized  using  0.1%  v/v  Triton  X‐100  in  PBS  for  15’.  Importantly,  for 
extracellular EGF staining, cells were not permeabilized. Cells were subsequently blocked 
with  5% w/v  non‐fat  dried milk  in  PBS  for  1  h  at  3  temperature  (RT).  Then,  cells  were 
incubated with  rabbit  anti‐EGF  (1:  500; Ab‐3,  Calbiochem) or  rat  anti‐E‐cadherin  (1:500; 
Abcam) primary antibody in PBS supplemented with 5% w/v non‐fat dried milk for 1 h at 
RT.  After  washing  in  PBS  three  times,  cells  were  incubated  with  anti‐rat  or  anti‐rabbit 
Alexa  Fluor  594  (1:1000;  Jackson  ImmunoResearch  Laboratories)  secondary  antibody  in 
PBS supplemented with 5% w/v non‐fat dried milk for 1 h at RT. Individual filters were cut 













First,  we  studied  the  fate  of  wild‐type  pro‐EGF‐GFP  (pro‐EGF‐WT)  and  pro‐EGF‐P1070L‐
GFP  (pro‐EGF‐P1070L)  expressed  in  non‐polarized  HEK293  cells.  To  this  end,  these  cells 
were  transiently  transfected  using  polyethylenimine  (PEI),  resulting  in  a  transfection 
efficiency of 30‐50%, which persisted for at  least one week. To compare the cell surface 
expression  of  pro‐EGF  to  total  expression,  biotinylation  experiments  were  performed. 
Immunoblotting  of  both  fractions,  using  the  GFP  antibody,  showed  robust  plasma 





membrane  localization, while  the  expression  of  pro‐EGF‐P1070L was  not  different  from 
pro‐EGF‐WT (Figure 4A).  
Second,  a  polarized  cell model was  employed  to  study  the  fate  of  these  proteins  in 
more  detail.  We  attempted  a  stable  transfection  of  MDCK  cells  with  pro‐EGF‐WT  and 
P1070L  in  the  pCB7  plasmid  (9),  using  the  calcium‐phosphate  precipitation  technique. 
However, some pilot experiments taught us that the expression of pro‐EGF in these cells 
was  undetectable  by  immunoblotting  (data  not  shown).  Next,  different  transient 
transfection  strategies  were  tested  using  various  transfection  reagents  under  variable 
conditions.  The  percentage  of  transfected  (GFP‐expressing)  cells  was  determined  using 
fluorescence microscopy. The results showed that a transfection efficiency of 10% was the 
maximum, with only 5% of the cells being positive three days  later  (the earliest stage to 
perform experiments)  (Table  1).  Finally,  an  inducible  cell  expression  system was  tested, 























EGF‐P1070L  in  MDCK  cells,  immunoblotting  was  performed.  Figure  3  shows  that  100 
ng/mL  doxycycline  is  necessary  and  sufficient  for  inducing  transcription  of  pro‐EGF. 





GFP  and  pro‐EGF‐P1070L‐GFP  using  the  GFP‐antibody  and  even  to  determine  the  total 
(apical  and basolateral)  plasma membrane  fraction, using biotinylation  (Figure 4B).  Cell‐
surface biotinylation showed a similar fraction of pro‐EGF‐WT and pro‐EGF‐P1070L on the 















(WT) and pro‐EGF‐P1070L‐GFP  (P1070L)  transcription was determined, using  immunoblotting with 
the GFP‐antibody. For this purpose, MDCKI and MDCKII cell  lines were transiently transfected with 
WT and P1070L. (A) The expression of WT as well as P1070L in MDCKI and MDCKII cells was tested 







The  next  day,  expression  of  pro‐EGF  was  induced  using  100  ng/mL  doxycycline.  Cell‐surface 
biotinylation of  these proteins was  analysed  in HEK293  cells  (A)  and MDCKI  and MDCKII  cells  (B), 









































































































































Figure  5.  Detection  of  (pro‐)EGF  in  the  medium  of  non‐polarized  MDCKI  cells  using 





fraction)  and  concentrated  using  centriprep  columns.  This  figure  represents  two  individual 
experiments.  (A) The  first experiment measured  (pro‐)EGF after 4 h and after 16 h  in  the > 50 kD 
medium  of MDCKI  cells  using  immunoblotting  (upper  part)  and  in  the  3‐50  kD  fraction  by  ELISA 
(lower part) in the corresponding samples. (B) The second experiment determined pro‐EGF after 4 h 
with PMA and after 16 h in the absence of PMA, in the > 50 kD medium. In addition, the total lysate 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seeded  on  semi‐permeable  filters.  Five  days  later,  protein  expression was  induced with 




kD  medium  fraction  revealed  that  the  170  kD  pro‐EGF  and  P1070L  proteins  are 
predominantly secreted into the apical compartment (Figure 6B and C, upper parts). This 
immunoblot revealed that no pro‐EGF is detectable  in the basolateral medium of MDCKI 





of  pro‐EGF‐P1070L  was  50%  lower  in  MDCKI  cells  and  25%  lower  in  MDCKII  cells.  In 




were  again  secreted  predominantly  into  the  apical  compartment;  however,  the 
abundance of pro‐EGF‐P1070L was around 40% of wild‐type. In this experiment 5% of the 
apical  pro‐EGF  released was  found  in  the basolateral medium, whereas pro‐EGF‐P1070L 
was not detectable  in  the basolateral  compartment.  Subsequent  immunoblotting of  the 
total cell lysate, using anti‐GFP and β‐actin antibodies, showed that the abundance in pro‐
EGF‐P1070L expressing cells was 85% and 75% of the wild‐type, respectively (Figure 7B). 
In  addition,  in  all  individual  experiments  only  the  large  170  kD  pro‐EGF  fragment  was 
perceived  in  the  >  50  kD  fraction  or  in  the  total medium  fraction;  no  smaller  (pro‐)EGF 
intermediates were observed.  
 
To  assess  the  processing  of  pro‐EGF‐WT  and  pro‐EGF‐P1070L,  detection  of  EGF  in  the 
various medium fractions was performed by ELISA.  In MDCKI cells,  the putative 170 kDa 
pro‐EGF‐WT and pro‐EGF‐P1070L are largely secreted into the apical compartment, similar 
to  the  results  obtained  by  immunoblotting.  After  16  h  the  pro‐EGF  abundance  in  the 
medium  was  triple  the  amount  of  the  4  h  medium.  Moreover,  the  3‐50  kD  fraction 
contained approximately three times higher EGF concentrations compared with the > 50 
kD protein  fraction (Figure 6D).  In addition, pro‐EGF secretion by MDCKII cells showed a 
















comparable  profile,  except  in  two  areas:  i)  the  EGF  concentrations were  approximately 






ELISA.  (A)  MDCK  cells  stably  transfected  with  pro‐EGF‐WT‐GFP  (WT)  or  pro‐EGF‐P1070L‐GFP 
(P1070L) were seeded on filters. Once the cells were polarized, expression of pro‐EGF was induced 
using  100  ng/mL  doxycycline.  24  h  later,  FCS‐free  medium  was  added  and  after  4,  16  or  48  h 
medium was collected and the protein fractions were separated and concentrated using centriprep 
columns.  Detection  of  pro‐EGF  after  16  h  in  the  medium  of  MDCKI  (B)  and  MDCKII  (C)  cells  by 
immunoblotting. Total  lysate was also blotted, using  the EGF and β‐actin antibodies  to determine 
the expression levels of WT and P1070L and the total protein input. The protein mass scale (in kD) is 
indicated on  the  left.  Side  specific  excretion of WT  and P1070L  after  4  or  16  h  in MDCKI  (D)  and 
























































































































































































































































































































































In  agreement  with  the  immunoblotting  results,  two‐three  and  three‐seven  times  lower 
concentrations were measured for the P1070L mutant in the secreted fractions of MDCKI 
and MDCKII cells, respectively. Moreover, an additional experiment showed that after 48 





Figure  7.  Detection  of  pro‐EGF  in  the 
medium  of  polarized  MDCK  cells  using 
immunoblotting.  Detection  of  pro‐EGF‐
WT‐GFP  (WT)  and  pro‐EGF‐P1070L‐GFP 
(P1070L)  after  16  h  in  the  medium  of 
MDCKI  cells  by  immunoblotting  (A),  also 
the total lysate was blotted, using the EGF 
and  β‐actin  antibodies  to  determine  the 
input (B). The protein mass scale (in kD) is 






To  investigate  the  subcellular  localization  of  pro‐EGF‐WT  and  pro‐EGF‐P1070L, 
immunocytochemistry  followed  by  confocal  microscopy  was  performed.  Hence,  MDCK 
cells  stably‐transfected  with  pro‐EGF‐WT  and  pro‐EGF‐P1070L  were  seeded  on  semi‐
permeable filters and protein expression was induced after three days. The next day, cells 
were  stained  using  an  anti‐E‐cadherin  or  anti‐EGF  antibody;  the  latter  was  used  for 
staining of  the  extracellular  EGF  epitopes only  (Figure  8A). MDCKII  cells  expressing pro‐
EGF formed a tight monolayer, whereas MDCKI cells expressing pro‐EGF did not establish 
confluent monolayers. Wild‐type  pro‐EGF  and  the  P1070L mutant were  both  principally 
expressed at  the apical membrane, which  is most  clearly  visualized by  the MDCKII  cells. 
Minor  basolateral  expression  of  pro‐EGF‐WT  and  pro‐EGF‐P1070L was  detected  in  both 
MDCK  cell  lines  as  well  (Figures  8B  and  C).  Finally,  the  effect  of  the metalloproteinase 
inhibitor  phenanthroline was  tested.  As  shown  in  the  right  panels  of  Figures  8B  and C, 






Fluorescent  staining  and  consecutive  confocal  analysis  of  polarized MDCK  cells  showed 
that  pro‐EGF‐WT  and  pro‐EGF‐P1070L  are  predominantly  sorted  to  the  apical  plasma 
membrane. Moreover, pro‐EGF‐WT and pro‐EGF‐P1070L are secreted by MDCK cells and 
processed  to produce  the mature 6 kD EGF hormone, presumably  in proportion  to  their 
abundance.  Finally,  abated  secretion  of  pro‐EGF‐P1070L,  into  the  apical  as  well  as  the 
basolateral compartment was observed, in comparison with wild‐type.  


















Figure  8.  Analysis  of  subcellular  localization  of  pro‐EGF‐WT‐GFP  (WT)  and  pro‐EGF  P1070L‐GFP 
(P1070L)  in  MDCK  cells,  using  immunocytochemistry  and  confocal  laser  scanning  microscopy 
(CLSM).  (A)  Schematic  overview  of  fluorescent  procedure  used;  the  EGF‐antibody  is  used  for 
detection of the membrane expressed WT and P1070L only. Confluent monolayers of the MDCKI (B) 
and  MDCKII  cells  (C)  were  stimulated  with  100  ng/mL  doxycycline  to  induce  WT  or  P1070L 
expression. MDCKI and MDCKII cells expressing WT or P1070L were left untreated or incubated with 






the overexpression of  these  large proteins  in MDCK  cells  and  the maintenance of  these 
cells was  laborious.  The  transfection efficiency of MDCK  cells with pro‐EGF‐WT‐GFP and 


































us  with  expression  levels  of  pro‐EGF‐GFP  high  enough  to  perform  the  outlined 
experiments.  
Using  the  T‐REx  system,  we  showed  that  pro‐EGF‐WT‐GFP  and  pro‐EGF‐P1070L‐GFP 
are  equally  located  in  the  total  plasma  membrane  fractions  of  HEK293  cells  and 
transiently‐transfected non‐polarized MDCK cells. Furthermore, secretion of pro‐EGF from 
transiently‐transfected  non‐polarized MDCK  cells  was  observed  from  4  h  onwards.  Our 
data  indicated  that  after  16  h  most  of  the  full‐length  pro‐EGF  is  processed  and  that 
secretion is decreased at that time point.  
Additional  experiments  performed  using  stably‐transfected,  polarized  MDCK  cells, 
found  that  pro‐EGF‐WT  and  the  P1070L mutant were  both  principally  expressed  at  the 







concentrations of pro‐EGF and P1070L were detected  in  the 3‐50 and > 50 kD  fractions, 
compared with 4 h. Within 4 h, the quantity of (pro‐)EGF in the 3‐50 kD protein fraction 
was  two‐three  times  higher  in  the  apical  compartment  of  polarized  MDCKI  cells, 
suggesting  that  pro‐EGF  is  en  masse  processed  into  mature  EGF  within  hours  upon 
secretion. Importantly, in MDCKII cells the apical EGF concentration was similar or slightly 
increased  in  the  3‐50  kD  apical  fraction.  In  the  basolateral  compartment  of MDCKI  and 
MDCKII cells  the abundance of EGF was two‐six  times  lower compared with the > 50 kD 





difference  between  these  cell  lines  is  that  a  monolayer  of  MDCKI  cells  has  a  higher 





transepithelial  electrical  resistance,  compared  with  an  MDCKII  cell  monolayer  (42). 
Whereas  pro‐EGF was  virtually  undetectable  in  the  basolateral medium  of MDCKI  cells, 
the basolateral media of MDCKII  cells  contained  significant amounts of pro‐EGF‐WT and 







times  higher  compared  with  the  apical  medium.  They  proposed  that  preferential 
ectodomain  cleavage  at  the  basolateral  surface  explains  the  apparent  abundant  apical 
localization  of  pro‐EGF  (40).  This  is  in  conflict  with  our  results,  which  show  increased 
abundance in the apical medium of pro‐EGF and mature EGF. Regardless of the different 




physiological  relevance of EGF  in urine  is not  clear,  considering  that EGFR  localization  is 
restricted to the basolateral side (10). It has been proposed that urinary EGF plays a role in 




unlikely  that  disturbed  sorting  to  the  basolateral  membrane  is  responsible  for  the 
phenotype  caused  by  the  mutation.  The  observed  secretion  defect  of  pro‐EGF‐P1070L 
probably only  impacts  the physiological effect of pro‐EGF at  the basolateral  side  for  the 
following  reasons:  i)  the  “threshold”  for  activation  of  EGFR  is  not  reached  due  to  the 
preferential  sorting  of  pro‐EGF  to  the  apical  side,  or  ii)  (pro‐)EGF  is  only  physiologically 
active the basolateral side of the DCT, since EGFRs are supposed to be located only at this 
domain.  The  experiments  performed  in  HEK293  and  transiently‐transfected MDCK  cells 




















towards  its  substrate  (36).  Cleavage  of  pro‐EGF  is  likely  to  be  independent  of  other 
regulators and determined mainly by the expression level of this protease (34). ADAM10 is 
constitutively  expressed  at  the  basolateral  membrane  of  human  DCT  (45).  In  addition 
endogenous  ADAM10  was  detected  in  this  membrane  domain,  primarily  at  cell‐cell 





in  renal  DCT  cells. We  showed  that  secretion  of  P1070L  to  the  apical  as  well  as  the  basolateral 




thereby  causing  renal Mg2+  loss.  Since  it  is  not  clear whether  EGF  has  a  physiological  role  at  the 
apical side, the consequence of reduced levels of (pro)EGF in pro‐urine due to the P1070L mutation 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concerted  actions  of  intestinal  absorption,  exchange with  bone  and  renal  reabsorption. 
Renal  adaptation  of  urinary  Mg2+  excretion  to  fluctuating  circumstances  is  the  most 
important of these mechanisms for maintaining a constant plasma Mg2+ concentration (1). 
In  the  proximal  tubule  (PT)  and  thick  ascending  limb  of  Henle’s  loop  (TAL)  Mg2+ 
reabsorption takes place in a passive and paracellular manner, secondary to Na+ and H2O 
transport. However,  fine‐tuning takes place  in the distal convoluted tubule  (DCT), where 
active  Mg2+  reabsorption  occurs  (2).  The  epithelial  Mg2+  channel  transient  receptor 
potential subfamily melastatin, member 6 (TRPM6) expressed in DCT has been identified 
as gatekeeper of active transcellular Mg2+ reabsorption (3). In recent years the molecular 
regulation  of  TRPM6  became  evident  via  the  discovery  and  characterization  of  several 
modifying  proteins  (4).  In  addition,  linkage  and  DNA  analysis  of  patients  suffering  from 
isolated autosomal recessive renal hypomagnesemia (IRH) uncovered a role for epidermal 
growth  factor  (EGF)  as  the  first  magnesiotropic  hormone  (5).  Moreover,  several  other 
hereditary  disorders,  which  have  hypomagnesemia  as  a  component  of  the  phenotype, 
indicated additional proteins essential for Mg2+ reabsorption in DCT or TAL (6). For most of 
them, their  function has been (largely) unraveled, whereas  for others  the exact  function 
remains obscure. This thesis focused on the impact of several drug treatments and dietary 
Mg2+  content  on  systemic  Mg2+  balance.  The  function  and  importance  of  individual 
“magnesiotropic  players”,  and  the  capacity  of  the  kidney  to  adapt  to  challenging 






Nowadays  drug  development  is  directed  against  defined molecular  targets  and when  a 
new drug is successfully launched, the molecular pathway is known. However, in the last 
century,  when most  of  the  drugs  still  in  use  today  were  discovered,  plural  approaches 
were  used.  Often,  trial‐and‐error  experiments  were  involved  and  compounds  were  of 
synthetic as well as natural origin, resulting in many effective drugs where the mechanism 
of  action  remained  elusive  (7).  As  a  consequence,  the  adverse  effects  of  several  drugs, 
uncovered  after  the  drug  was  already  marketed,  accelerated  insight  into  human 
physiology (8, 9). The annual worldwide spending on medications is expected to exceed 1 
trillion dollars in 2015 (10). In particular, elderly and chronically ill patients use a variety of 
drugs  (11).  For  certain  drugs,  aberrations  in Mg2+  handling  have  been  described  as  side 
effect.  For  instance,  some  antineoplastic  agents  and  calcineurin  inhibitors  can  cause 










In  Chapter  2  the  mechanism  by  which  Cis‐Diamminedichloroplatinum(II)  (Cisplatin) 
treatment causes hypomagnesemia was studied. Cisplatin is a widely used cytostatic drug 
with  a  broad  range  of  actions  in  the  treatment  of  solid  tumors  (13).  This  chemical  kills 
cancer  cells  by  cross  linking  RNA,  DNA  and  protein  in  rapidly  dividing  cells  (14). 
Unfortunately, renal toxicity, and more specifically damage to the PT and DCT segments of 
the nephron,  restricts  treatment  (15‐18). Around 20% of  the patients  treated with high‐
dose cisplatin develop renal dysfunction, which frequently leads to acute renal failure (19‐
21).  However,  most  of  the  patients  treated  with  cisplatin  develop  severe 
hypomagnesemia  (22,  23),  often  associated  with  a  reduced  glomerular  filtration  rate 
(GFR),  polyuria  and  other  electrolyte  disturbances  (24‐27).  It  was  previously  suggested 
that  toxicity  to the DCT  is  responsible  for cisplatin‐induced hypomagnesemia  (1, 28, 29). 
Therefore,  the  purpose  of  our  study  was  to  unravel  the  pathway  by  which  cisplatin 
therapy  causes  renal  Mg2+  wasting.  For  this  experiment,  mice  were  treated  with  3 
intraperitoneal injections containing 5 mg/kg body weight cisplatin or vehicle, with 3 non‐
treatment days between injections and after the last treatment.  




increased  in  the  cisplatin‐treated  group,  whereas  the  excretion  of  Pi  was  not  affected. 
Analysis  of  the  mRNA  expression  levels  of  different  ion  transporters  and  associated 
proteins revealed specific downregulation of TRPM6, the Na+, Cl‐ cotransporter (NCC) and 
parvalbumin  (PV),  which  are  typically  expressed  in  the  DCT.  Experiments  measuring 
corresponding protein levels confirmed the decreased expression of these proteins. These 
results strongly support an increased susceptibility of the DCT to cisplatin. It  is likely that 
downregulation  of  TRPM6  in  the  DCT  causes  the  observed  Mg2+  loss,  since  active 
reabsorption  of  Mg2+  through  this  channel  determines  the  final  plasma  Mg2+ 
concentration,  and  other  parts  of  the  tubule  are  largely  impermeable  to  Mg2+. 
Interestingly,  several  genes  specifically  expressed  in  the PT were not  affected. Although 
kidney  injury  molecule‐1  (Kim‐1)  mRNA  levels  were  impressively  upregulated  upon 
treatment  with  cisplatin,  aquaporin  1  (AQP1),  the  Na+,  H+  exchanger  3  (NHE3)  and  the 
sodium‐glucose  cotransporter  1  (SGLT1)  expression  levels  were  equal  between  the 
cisplatin‐treated group and the control group. Possible explanations are that PT damage is 
less  severe,  or  that  it  is  different  from  DCT  toxicity,  in  that  general  destruction  via 
oxidative stress and necrosis prevail in PT (20).  
Theoretically,  two  mechanisms  could  explain  DCT‐specific  toxicity:  i)  local  entry  of 





that  this  transporter  is  responsible  for  cisplatin  toxicity  in  the  DCT.    Confirmation  that 
CTR1 is downregulated on protein level in the cisplatin group would be essential. Blocking 
the  entry  of  cisplatin  via  this  transporter,  using  copper  sulfate  (31),  could  verify  its 
contribution  to  cisplatin‐induced  toxicity  in  the  kidney.  Alternatively,  mitochondrial‐








death  (33,  34).  DCT  cells  are  characterized  by  the  large  size  and  multiplicity  of 
mitochondria (35). Augmented sensitivity to cisplatin based on mitochondrial density has 
been  shown  in  vitro  (36).  Immunohistochemical  staining  of  cisplatin‐treated  kidney 
sections  for  NCC  and  PV  suggested  that  specific  protein  downregulation,  rather  than 
major  cellular  damage,  is  responsible  for  cell  death.  This  was  confirmed  by  light 
microscopy,  showing  clear  indications  of  individual  necrotic  tubular  epithelial  cells, 
detachment of cells and some urinary casts; however, this damage was limited (Chapter 2; 
unpublished results). 
Finally,  discovering  how  to  block  uptake  or  targeting  of  cisplatin  to  the  DCT  in  a 
clinically  practical  manner  would  be  the  ultimate  route  to  reduce  renal  side  effects. 
Alternatively, inhibition of PKCδ (37) and infusion of adipose tissue‐derived mesenchymal 
stem cells (38) have been proposed as candidate strategies to attenuate cisplatin‐induced 
damage  and  to  restore  kidney  function.  Cisplatin  will  likely  remain  the  best  treatment 
option for different solid tumors, as it is highly efficacious. However, the continued search 
for  the  optimal  combination with  other  platinum‐based  drugs,  non‐platinum  anticancer 
agents and/or specific cellular targets, might further improve its potential (34, 39).  





Furosemide has been widely used  since  the 1960s  for  treating hypertension and edema 
(9).  Today,  this  compound  is  still  regularly  prescribed,  often  in  combination  with  other 
diuretics  (40, 41). Furosemide blocks  the Na+, K+, 2Cl‐ cotransporter  (NKCC2)  in TAL  (42). 
Consequently,  Na+  reabsorption  is  diminished,  which  results  in  decreased  urine 




the  clinical  effect  of  furosemide  were  performed  in  cohorts  of  patients  with  a  specific 
disease.  
Chapter  3  examined  the  effect  of  chronic  furosemide  use  on  the  total Mg2+  status, 
focusing  on  reabsorption  of  Mg2+  by  the  kidney.  Mice  were  treated  for  7  days  with 
furosemide using osmotic minipumps, which subcutaneously released the dissolved drug 
in  a  continuous  manner.  The  mice  chronically  treated  with  furosemide  developed  a 
significant polyuria.  In addition,  these mice displayed  increased serum concentrations of 
Na+,  whereas  serum  K+,  Ca2+  and  Mg2+  values  were  not  significantly  altered  in  those 
animals. Moreover, the urinary excretion of Na+, K+, Ca2+ and Mg2+ was not affected by the 
furosemide  treatment.  Our  results,  obtained  with  mRNA  and/or  protein  level 
measurements, revealed specific upregulation of TRPM6, NCC, the epithelial Ca2+ channel 
(TRPV5)  and  calbindin‐D28K,  whereas  PV,  claudin‐7  (CLDN7)  and  claudin‐8  (CLDN8),  the 
epithelial Na+ channel (ENaC) and NHE3 were not affected.  
These  findings  suggested  that  the  DCT  can  compensate  for  impaired  paracellular 
reabsorption  of  Mg2+  in  the  TAL  by  increasing  TRPM6‐mediated  transcellular  Mg2+ 
transport during blockade of NKCC2 by  furosemide. The  increased Mg2+ delivered to  the 
DCT  results  in  a  luminal  Mg2+  concentration  favourable  to  Mg2+  transport,  and  in 













drug  (50).  Our  findings  regarding  the  compensatory  adaptation  of  Na+  and  Ca2+ 
reabsorption  are  in  line  with  the  upregulation  and/or  increased  activity  of  NCC  and 
calciotropic players in response to furosemide, as reported by others (46, 51‐53). As far as 
we know, our study is the first to describe the upregulation of TRPM6 in mice treated with 




TRPM6 blocker has not  yet been discovered or designed. A  conditional  knockout model 
might  offer  a  solution.  Alternatively,  assessing  the  co‐treatment  of  furosemide  and 
thiazide,  might  confirm  the  adaptive  role  of  the  DCT  as  observed  in  this  chapter. 
Hypomagnesemia induced by thiazide treatment and in the NCC knockout mice has been 
associated  with  downregulation  of  TRPM6  (43).  Previous  publications  indicate  that 
combination  therapy  enhances  Na+  excretion  and  urinary  production  (41).  Moreover, 
urinary Mg2+ excretion is likely in between the amounts of Mg2+ excreted upon treatment 
with  thiazide or  the  loop diuretic  furosemide alone  (43, 55); however,  the effect on  the 
Mg2+ balance needs to be further established, especially on the long term.  
The  present  study  found  that  mice  treated  with  furosemide  effectively  lose  fluid 
without  serious electrolyte  imbalances. Adequate  renal  function  is an essential  requisite 
for  adapting  reabsorption  of  Mg2+,  as  well  as  Na+,  K+  and  Ca2+,  to  avoid  electrolyte 
imbalances. However, renal function is critical in many patients treated with furosemide. 
Hypertension  is  a  common  cause  of  chronic  kidney  disease  (CKD)  and  vice  versa  (56), 
which  explains  why  electrolyte  aberrations  might  be  diagnosed  in  this  cohort  (57).  In 
addition  to  sufficient  renal  function,  an  adequate  diet  is  also  of  vital  importance  for 
optimal  treatment  with  furosemide.  Dietary  intake  of  Mg2+  is  often  problematic  in 
seriously  ill  patients  or  the  elderly  (58‐60);  again,  the  very  people  who  are  prescribed 






Human  beings  are  dependent  on  sufficient  dietary  Mg2+  intake  from  the  external 
environment.  Fortunately, Mg2+  is  an  essential  element  of  biological  systems  in  general, 












Insight  into  the  network  of  proteins  essential  for  Mg2+  reabsorption  has  significantly 
increased  in  the  past  decade.  Several  proteins  involved  in  Mg2+  homeostasis  were 
uncovered,  as well  as  part  of  their  interactions  and  regulating  factors.  In Chapter  4  the 
sensitivity of these recently discovered magnesiotropic players to changes in dietary Mg2+ 
content was determined. Mice were placed on a Mg2+‐deficient or  a Mg2+‐enriched diet 
for  two  weeks.  Dietary  Mg2+  restriction  resulted  in  a  significant  hypomagnesemia  in 
combination  with  markedly  reduced  urinary  excretion  of  Mg2+,  in  line  with  previous 





investigation.  Regulation  of HNF1B  indicates  that  basolateral Mg2+  transport  in DCT  is  a 
critical  process.  Further  research  into  HNF1B  could  uncover  the  mechanism  for  Mg2+ 
extrusion into the blood compartment (1). PV has been originally classified as Ca2+‐binding 
protein (63); however, the present study suggests that its role in the DCT might be more 
extensive.  It  likely  affects  the  activity  of NCC and/or  can bind Mg2+  and  consequently  is 
directly  or  indirectly  entangled  in Mg2+  reabsorption.  Although  PV  knockout mice  were 
normomagnesemic,  they  showed  increased  diuresis,  urinary  K+  excretion  and  elevated 
aldosterone levels (64). In addition, the level of NCC in the PV knockout mice was reduced, 
which might be a  consequence of  impaired  [Ca2+]i  buffering.  Electrolyte  reabsorption by 
NCC has been suggested to be essential for Mg2+ transport in DCT (65, 66). Since we found 
that  NCC  levels  were  downregulated  and  PV  levels  upregulated  in  our  dietary  Mg2+‐






regulated  on  protein  level;  ii)  post‐transcriptional  activation  is  of major  importance  for 
these  transcripts  (67)  or;  iii)  their  activity  might  be  regulated  by  internal  dynamics  or 
protein‐protein  interactions  (68, 69). Furthermore,  the mRNA expression  level of TRPM6 
in  the  colon was  also markedly  increased  during  dietary Mg2+  restriction.  This  indicates 
that regardless of the renal adaptations, the capacity for transcellular Mg2+ absorption is 
enhanced.  
Finally,  TRPM6 expression was not only observed  in  kidney and  intestine,  it  has  also 
been  attributed  to  lung  tissue  (62).  Our  unpublished  PCR  data  showed  that  TRPM6  is 
expressed  in  the  trachea  as  well.  Immunohistochemical  staining  was  performed  for 
TRPM6; unfortunately, the specificity of the antibody in these samples was questionable. 
Therefore,  in  situ  hybridization  would  be  an  appropriate  tool  to  localize  TRPM6  and 
subsequently  define  its  function  in  the  respiratory  system.  This  is  clinically  interesting, 
since  Mg2+  treatment  has  been  shown  to  induce  relaxation  of  bronchial  cells  and 
ameliorate obstructive lung diseases like asthma (70, 71). It might be that TRPM6 plays an 
essential  role  in Mg2+ signaling  in  the  lung and that more  insight  into pulmonary TRPM6 
could contribute to improved lung function of many patients.  











interesting  clues  about  the  regulation  of  Ca2+  and  Mg2+  reabsorption.  First  of  all,  we 
observed  that  dietary  Mg2+  intake  affects  not  only  renal  Ca2+  reabsorption,  but  also  Pi 
reabsorption,  albeit  in  the  opposite  direction.  The  serum  Pi  level  was  increased  in  the 
Mg2+‐deficient  mice  compared  with  the  Mg2+‐enriched  mice.  Second,  the  serum  FGF23 
level was  two  and  a  half  times  higher  in  the mice  fed  the  low Mg2+  diet.  These  results 
indicated that  the postulated reduction  in renal Pi  reabsorption  in  the PT  is preceded by 
the increased FGF23 in the hypomagnesemic mice (74). It might be that increased serum 
Pi stimulates the elevation of FGF23 (75). Further investigation is needed to establish the 
mechanism  by  which  serum  Pi  and  FGF23  are  linked.  Importantly,  the  electrolyte 
imbalances observed in our dietary Mg2+‐restricted mice correspond to the clinical picture 
of  patients  with  persistent  hypomagnesemia  accompanied  by  hypoparathyroidism,  and 
consequently hypocalcemia  in  combination with hyperphosphatemia  (76, 77).  Third,  the 
expression of TRPV5 and calbindin‐D28K was markedly downregulated during dietary Mg
2+ 
restriction  on  both  the  mRNA  and  protein  levels.  Nearly  all  Ca2+  is  reabsorbed  by  the 




secondary  hypocalcemia  in  the  hypomagnesemic  mice.  Parathyroidectomized  rats  had 
similarly reduced TRPV5 and calbindin‐D28K  levels, which were normalized upon  injection 
with  parathyroid  hormone  (PTH)  (78).  Unfortunately,  it  was  not  possible  to  directly 
measure PTH levels, since we collected serum from our mice and plasma is required for a 
PTH assay. Nevertheless,  in patients hypomagnesemia  is often accompanied by  low PTH 
levels, which  could be  restored by Mg2+  supplementation  (72, 79, 80). Most  likely, Mg2+ 
depletion  causes  impaired  secretion and/or  synthesis of PTH  (81)  and  resistance  to PTH 
(82,  83),  resulting  in  downregulation  of  TRPV5  and  calbindin‐D28K.  This,  combined  with 
disordered bone metabolism, explains the secondary hypocalcaemia (73).  
The binding of PTH to its receptors in bone is hindered during hypomagnesemia. It was 
demonstrated  that  decreased  uptake  of  PTH  and  reduced  PTH‐stimulated  cAMP 
production by bone causes skeletal  resistance  to PTH  in chronically Mg2+‐restricted dogs 





seems  to  obstruct  PTH  secretion  (87),  perhaps  by  limiting  the  function  of  Mg2+  as  a 
second‐messenger  (88); however,  the details  are not  yet elucidated.  In  vitro  and  in  vivo 













dietary  Mg2+  intake  affects  many  people  worldwide,  especially  those  of  a  lower 
socioeconomic  status,  and  woman  and  the  elderly  are  especially  at  risk  (89‐94).  The 
consumption  of  a  well‐balanced  diet,  which  includes  a  variety  of  fruits,  vegetables, 
legumes and cereals  (like for the “Healthy Eating Pyramid”) should fulfill  the Mg2+ needs 
(91,  95).  Unfortunately,  many  people  do  not  consume  such  a  diet.  In  industrialized 
countries, the average diet contains too much added sugar, saturated fat and insufficient 
nutrients (96). Education campaigns, and maybe even measures like financial incentives to 
consume certain  foods  should be considered. Mg2+  supplementation has been shown to 
be beneficial for different physiological processes (97‐100). Further research is needed to 
determine whether standard Mg2+ supplementation in specific population groups, like the 
elderly,  should  be  advised.  Some  people,  such  as  elite  athletes  and  pregnant  women, 
likely  have  an  increased  daily  Mg2+  requirement  (101,  102).  Mg2+  supplementation  has 
been  shown  to  be  beneficial  in  the  treatment  of  muscle  cramps  and  to  reduce  the 
occurrence of pre‐eclampsia (103, 104). 
Although  cardiac  and metabolic  health  is  likely  affected  by  insufficient  dietary Mg2+ 
intake (99, 100), the clinical  impact is not completely assessed. However, as described in 
the  general  introduction  of  this  thesis,  different  groups  of  patients  are  at  risk  of 
developing  severe  hypomagnesemia,  with  potentially  life‐threatening  consequences. 
When  drugs  affecting  Mg2+  homeostasis  are  prescribed  and/or  patients  have  impaired 
kidney function, regular monitoring of the Mg2+ status is especially crucial (105, 106).  
Various methods exist  to determine Mg2+ deficiency; unfortunately each of them has 
limitations. Some methods accurately  reflect  the  total body Mg2+  level,  including muscle 
or  blood  cell measurements;  however,  they  are  neither  practical  nor widely  applicable. 
The assessment of only ionized serum Mg2+ might better reflect the Mg2+ status than total 
serum  Mg2+  (107),  but  the  large  same‐day  variability  requires  multiple  measurements 
(108).  Therefore,  determination  of  the  total  serum  Mg2+  concentration  in  combination 
with  24‐hour  urinary  Mg2+  excretion  is  advised.  This  often  provides  a  good  clinical 




Once  the  indication  for  Mg2+  supplementation  is  assessed,  different  routes  of  Mg2+ 
administration  are  possible.  Depending  on  the  underlying  disease(s)  and  severity  of 
hypomagnesemia,  the  condition  of  the  patient  and  whether  or  not  the  patient  is 
hospitalized,  the  attending  physician  can  opt  for  oral  supplementation,  intramuscular 
injections  or  intravenous  infusions  (12,  110).  For  patients  treated  with  cisplatin, 
supplementation  of  the  pre‐  and  post‐hydration  fluids  with  Mg2+,  combined  with  oral 
supplementation  in between courses had beneficial  treatment outcomes  (28, 106, 111). 
For patients treated chronically with diuretics, oral Mg2+ supplementation could normalize 
body  Mg2+  (112,  113).  Co‐treatment  with  Mg2+  was  positively  applied  in  many  other 
treatment  strategies  (114‐116).  Importantly,  regular  monitoring  of  all  these  patients  is 
essential to ascertain the intended effect and to adapt the therapy when necessary.  








DCT  in  Mg2+  homeostasis.  Treatment  with  the  cytostatic  agent  cisplatin  resulted  in 
downregulation  of  the  DCT  specific  proteins  TRPM6,  PV  and  NCC,  providing  a  plausible 
explanation  for  development  of  hypomagnesemia.  It  is  likely  that  the  decreased 
abundance  of  TRPM6  following  cisplatin  treatment  is  mediated  indirectly,  perhaps  via 
alterations  in  the mitochondria  resulting  in  impaired energy metabolism, or by a shift  in 
the  electrochemical  gradient  (117).  The  cisplatin  study  also  revealed  that  CLDN16  is 







induced  by  decreased  expression  of  TRPM6  in  the  distal  convoluted  tubule  (DCT).  The  upstream 
molecular  pathways  for  TRPM6  downregulation  are  different.  Cyclosporin  A  results  in  reduced 
transcription of c‐Fos, whereas the triggers for TRPM6 downregulation upon cisplatin and tacrolimus 
therapy remain elusive. Impaired energy release by mitochondria and a reduced insulin level might 
be  involved,  respectively. NCC expression  level was downregulated  in  cisplatin  and  cyclosporin A‐
treated rodents; however,  it was not affected  in  tacrolimus‐treated rats. Whether NCC expression 
level and/or activity influences Mg2+ transport via TRPM6 needs to be investigated. 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treated  with  the  immunosuppressant  tacrolimus.  They  found  that  tacrolimus‐induced 
hypomagnesemia  is associated with downregulation of TRPM6, whereas NCC abundance 
was  not  affected  (118).  Moreover,  in  vitro  and  in  vivo  experiments  revealed  that 
cyclosporin  A,  another  immunosuppressant  drug  affecting  Mg2+  homeostasis  (119), 
downregulates  TRPM6  (120,  121).  Cyclosporin  A  also  downregulates  NCC  and  reduces 
aldosterone  levels  (121). These drug studies revealed that when the DCT  is affected and 
TRPM6 is downregulated, there are radical consequences for Mg2+ balance. However, the 
molecular pathway leading to the downregulation of TRPM6 in tacrolimus‐treated rats has 
not  yet  been  unraveled.  The  significantly  increased  serum  glucose  levels  found  (118), 
might offer a clue, via impaired insulin secretion. Since insulin has been shown to bind to 
the insulin receptor in the DCT and stimulate TRPM6 activity, failure to stimulate TRPM6 




when dietary Mg2+  is  restricted, and  in  response  to drugs affecting Mg2+  reabsorption  in 
PT/TAL.  
The dietary restriction experiment described in this thesis showed a tight correlation in 
the  serum  Mg2+  level  with  the  urinary  Mg2+  excretion  in  the  experimental  mice.  The 
upregulation  of  TRPM6,  HNF1B  and  PV  and  the  downregulation  of  NCC  indicated  the 
adaptability  of  the DCT,  in minimizing  the body’s Mg2+  loss  during  the  low dietary Mg2+ 
regime.  In  addition,  enhanced Mg2+  reabsorption  in  the DCT  via  upregulation  of  TRPM6 
and NCC was sufficient  to compensate  for  the decrease  in Mg2+  reabsoprtion  in  the TAL 
during furosemide treatment, to prevent a hypomagnesemic state (Figure 2).  
Moreover,  in  rats  treated  with  the  immunosuppressant  dexamethasone,  TRPM6  was 
upregulated as well (118). This indicates compensation by the DCT and that the observed 
hypomagnesemia and hypermagnesiuria were caused elsewhere, likely further upstream, 
in  the  nephron.  Interestingly,  NCC  was  also  upregulated  in  the  rats  treated  with 
dexamethasone  (118).  The  antibiotic  drug  gentamycin  induces  Mg2+  and  Ca2+  wasting, 
which  rarely  results  in  serious  effects  on  serum  levels  of  these  ions.  This  is  conceivably 
effectuated by stimulation of CaSR and the subsequent reduced reabsorption of Mg2+ and 
Ca2+ via NKCC2 in TAL (123, 124). Compensation by DCT/CNT, similar to what was observed 





that  these  proteins  might  be  similarly  regulated,  for  example  via  the  acid‐base  status. 
However, the observation that TRPM6 is downregulated in response to chronic metabolic 
acidosis  (126)  while  NCC  is  upregulated  (127)  makes  this  co‐regulation  less  likely.  In 
addition,  the  dietary  Mg2+  study  revealed  that  although  limiting  Mg2+  results  in  the 
upregulation of TRPM6, NCC is not regulated on the mRNA level and even downregulated 
on the protein  level. Moreover,  in  the tacrolimus‐treated rats  the NCC protein  level was 
not  affected,  as  observed  in  the  cisplatin  and  cyclosporin  A  experiments.  Alternatively, 
since  TRPM6  and  NCC  are  co‐localized  on  the  apical  membrane  of  DCT  cells,  TRPM6 










drugs affecting Mg2+  reabsorption  in PT/TAL. Aberrations of  the Mg2+ balance  induced by dietary 
Mg2+  restriction  and  treatment  with  the  drugs  furosemide,  dexamethasone  and  gentamycin  are 
accompanied by  increased expression of TRPM6 in the distal convoluted tubule (DCT). Furosemide 
directly  blocks  NKCC2  in  the  thick  ascending  limb  of  Henle’s  loop  (TAL),  and  gentamycin  likely 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Decreased  Na+  reabsorption  in  PT/TAL  and  the  concomitant  increased  distal  Na+  load 
might be the initiator of increased Na+ reabsorption via NCC, followed by upregulation of 
TRPM6.  In  the case of  limiting dietary Mg2+,  furosemide, dexametasone and gentamycin 
experiments,  this  hypothesis  appears  to  be  valid,  but  direct  confirmation  is  missing. 




Whereas  TRPM6  upregulation  and  adaptation  of  the  DCT  in  general  is  quite  well 
established,  in  response  to  factors  affecting  Mg2+  reabsorption  in  the  kidney,  the 
adaptability  of  the  TAL  is  less  clear.  Interestingly,  besides  the  observed  upregulation  of 
CLDN16 expression in the cisplatin study, the mRNA level of CLDN16 was also significantly 
upregulated in the furosemide‐treated mouse group (194 ± 12 and 100 ± 8%, furosemide 
versus  control,  P  <  0.01,  data  not  shown).  However,  the  mouse  group  fed  the  Mg2+‐
restricted  diet  and  the  cyclosporin  A‐treated  rats  displayed  no  CLDN16  (or  CLDN19) 
upregulation,  compared  with  the  enriched  Mg2+  diet  mouse  group.  Obviously,  the 
abundance of tight junctions cannot be increased; changing the expression profile of the 
CLDNs affects only  the  selectivity of  the permeability  to  the different electrolytes  (129). 
The  ionic  composition  of  the  pro‐urine  in  combination  with  the  electrochemical 
membrane  potential  probably  determines  the  paracellular  transport  characteristics. 
Nevertheless, the presence of functional CLDN16 and CLDN19 proteins  is essential, since 
mutations in both tight junction members disturb Mg2+ reabsorption (130, 131).  
Finally,  the  EGFR  antagonist  cetuximab,  prescribed  for  the  treatment  of  cancer,  has 
been associated with hypomagnesemia and corresponding lower survival rates (132‐134), 
likely  due  to  the  blockage  of  TRPM6  activation  via  EGF  (5,  135).  Unfortunately,  the 
expression  levels  of  TRPM6  and  NCC  during  this  treatment  remain  to  be  investigated. 
Ironically, the efficiency of Panitumumab, a look‐alike of cetuximab and also targeting the 
EGFR, can be determined by the occurrence of hypomagnesemia during treatment (136). 
More  research  is  necessary  to  unravel  whether  there  exists  a  certain  degree  of 
interdependence between TRPM6, NCC and/or PV and if upstream co‐regulators of these 
proteins play a role in this. 
In  summary,  the  results  presented  in  this  thesis,  together  with  many  other  studies 
investigating  the  effect  of  other  Mg2+  homeostasis  affecting  drugs  in  the  literature, 
indicate  an  enormous  adaptability  of  the  DCT  for  Mg2+  reabsorption.  The  pernicious 







al.  found that  IRH is caused by a mutation  in the EGF gene encoding the  large precursor 
EGF  (pro‐EGF)  (5).  The  authors  suggested  that  the  observed  hypomagnesemia  in  these 
patients  is  the  consequence  of  impaired  activation  of  EGFR,  located  in  the  basolateral 
plasma  membrane  of  the  DCT,  and  subsequent  impaired  stimulation  of  TRPM6  (5).  In 
Chapter 5, the fate of the P1070L mutation in the cytoplasmic tail of pro‐EGF was studied 





in more  detail,  using  different  biochemical  approaches.  Stable MDCKI  and MDCKII  cells 
were made, using  the Tetracycline‐Regulated Expression  (T‐REx)  system.  Interestingly,  in 
HEK293  cells  and  in  non‐polarized  MDCK  cells,  pro‐EGF‐P1070L  plasma  membrane 
expression and secretion showed the same profile compared with wild‐type pro‐EGF (pro‐
EGF‐WT).  In  polarized  cells  both  proteins  were  predominantly  located  on  the  apical 
membrane and secreted and processed into 6 kD EGF at this side of the cell. However, the 
MDCK  cell  lines  also  sorted  pro‐EGF‐P1070L  and  pro‐EGF‐WT  to  the  basolateral 
membrane,  and  these  proteins  were  secreted  into  the  basolateral  compartment. 
Importantly, the secretion of the mutant was decreased on both the apical as well as the 
basolateral  side.  Our  results  suggested  that  the  point  mutation  results  in  impaired 
cleavage of pro‐EGF‐P1070L. The hypomagnesemia diagnosed in the patients affected by 
the mutation  is probably  caused by  the  impaired  stimulation of  EGFR at  the basolateral 
side  due  to  the  failure  to  reach  a  threshold  concentration  of  secreted  EGF,  which  is 
needed for stimulation of EGFR at this side of the cell. It has been suggested that pro‐EGF 
contains  a  basolateral  sorting motif  (5),  or  that  it  is  equally  distributed  on  both  plasma 











of  the experiments.  In  addition, many  researches used  a non‐polarized  cell model  (137, 
141), and sometimes not of renal origin (142‐145), which makes it difficult to integrate all 
the data. Furthermore, it is unclear to what extent these data can be extrapolated to the 
in  vivo  situation.  We  observed  that  secretion  of  pro‐EGF‐P1070L  and  pro‐EGF‐WT  in 
polarized  MDCK  cells  was  prolonged  when  compared  with  non‐polarized  transiently‐
transfected  cells,  indicating  that  the  process  of  sorting  and/or  cleavage  is  different.  In 
addition, Hobert et al. created an increased apical fraction of EGFR, by overexpression of 
this  receptor,  and  found  that  apical  EGF  activation was  less mitogenic  when  compared 
with  the  basolateral  effect.  They  suggest  that  this  difference  could  be  due  to  plasma 
membrane  domain‐specific  factors,  such  as  the  organization  of  the  cytoskeleton  (146). 
Moreover, the study model is also of major importance to investigate the shedding of pro‐
EGF  by  ADAM10  or  another metalloprotease.  The  abundance  of  endogenous  proteases 
could be limiting, given the nature of the overexpression system and this could potentially 
affect  the outcome of our experiments. Hence,  the exact physiological pathway of EGFR 
stimulation should be revealed by  future studies  including  in vivo  imaging of  fluorescent 
(pro‐)EGF mice with confocal microscopy. Finally, the construction of a transgenic kidney 
specific  P1070L mouse model would be  valuable  to  gain more  insight  into  regulation of 
Mg2+ transport in DCT. These efforts will conceivably reveal the specific conditions under 
which activation of the EGFR by EGF is of crucial importance for the stimulation of TRPM6 














Most  research conducted  for  this  thesis was performed using  the mouse as a model  for 
human beings. The mouse genomic sequence  is highly similar  to that of humans, due to 
the  small  evolutionary  distance  (147).  Although  species  like  primates  are  even  more 
closely related to humans, mice are easy to handle and less expensive to maintain. Their 
short  life  span  and  reproductive  cycle make  it  possible  to  study  disease  processes  and 
generate  (transgenic)  mice  relatively  quickly.  The  scientific  questions  addressed  in  this 
thesis were often  focused on a  specific mechanism, which could not be studied without 
considering  the  physiological  environment,  i.e.  the  whole  organism  and  its  natural 




research,  supported  by  the massive  knowledge  this model  already  brought  us  (148).  In 
addition, availability of humanized mouse models,  this means mice that received human 




In  the  mice  studies  described  in  this  thesis  (Chapters  2,  3  and  4)  we  made  use  of 
metabolic cages.  In 1988 Campbell and Oldham patented the metabolic cage unit,  in the 




body  weight  and  observation,  to  deduce  general  well  being,  and  when  necessary  to 
exclude a particular mouse. The disadvantage that is coupled to the use of these cages is 
the  stress  it  entails  for  the mice.  This  is mainly  induced  by  isolation,  the  unpredictable 
situation  and  by  the  fact  that  they  have  to  reside  on  a  grid  for  optimal  collection  of 
excrement,  which  prevents  them  from  behaving  naturally  (150).  To  minimize  the 




Traditionally, male mice are preferentially used  for biomedical  research  (152).  The main 
reason  is  the  widely  held  belief  that  female  mice  are  intrinsically  more  variable  than 
males,  due  to  their  cyclical  reproductive  hormones.  Although  this  influence  is  probably 
minor,  the  employment  of  both  genders would  be  preferential  in  research,  to  create  a 
reflection of  the human population  (153). The major disadvantage to using male mice  is 
aggression, which might affect the experimental outcome.   Fortunately, there exist ways 
to  minimize  aggressive  behavior,  for  example  by  spraying  lavender  scent.  For  the 






for  Chapter  2  female  mice  were  used. We  anticipated  serious  distress  due  to  cisplatin 
treatment, and preferred to use female mice to minimize the chance of dropouts due to 
fighting  in  combination with  their  weakened  condition.  Different  studies  have  reported 
gender‐related  differences  on  several  parameters  measured  during  cisplatin  treatment. 
For  example,  it  has  been  shown  that  estrogen  blocks  the  protective  effect  of 





effective,  whereas  a  higher  peak  sodium  excretion  rate  in  male  subjects  was  observed 




Age  is  likely  a more  important  parameter  than  gender,  especially  concerning  treatment 
with  diuretics,  like  furosemide  (159,  160).  The  indication  for  furosemide  treatment  is 
highest  in  the  elderly  (161,  162),  as  the  prevalence  of  hypertension  increases with  age 
(163).  This  cohort  of  patients  often  suffers  from  multiple  chronic  diseases.  The 
consequence is that the elderly take multiple medications, which increases the danger of 
complications due  to drug‐drug  interactions  (164). Multiple medications,  in  combination 
with  declined  organ  function,  especially  of  liver  and  kidney,  further  hampers  successful 







Figure  3  summarizes  the main  findings  and  limitations  of  the  experiments  presented  in 
this  thesis.  Clinical  recommendations  concerning  Mg2+  balance  and  future  research 
challenges are listed. The discovery of mutations in the DCT resulting in a phenotype that 



























Adaptability of the DCT
! In response to:
• Dietary Mg2+ regime
• Loop diuretics
! Toxicity of DCT to cisplatin 
results in hypomagnesemia
Limitations
! Mice as model for humans
! Serum Mg2+ concentration 
representing the “body 
Mg2+ status”
! mRNA level or protein 
level as indicator of 
protein activity
Clinical 
! Promote consumption of a healthy diet to 
fulfill the Mg2+ needs 
! Consider Mg2+ supplementation for 
subgroups like the elderly, athletes and 
pregnant women
! Monitoring patients susceptible to 
(generation of) hypomagnesemia, i.e.:
• IC patients
• Chronically ill patients, especially with 
impaired kidney function
• Patients treated with drugs known for 
Mg2+ wasting side-effect
Future perspectives
! Role of PV and HNF1B in DCT
! Extrusion of Mg2+ at basolateral 
side
! Establish whether Mg2+ 
reabsorption via TRPM6 is 
dependent on NCC activity
! Exact localization and function of 
TRPM6 in lung
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aanbevolen  inname  aan  Mg2+  voor  volwassenen  is  350  mg.  Zaden,  granen,  groene 
bladgroenten,  peulvruchten  en  noten  zijn  de  rijkste  Mg2+  bronnen,  echter,  enkel  in 
onbewerkte vorm. 
Regulatie  van  de  Mg2+  balans,  resulterend  in  een  Mg2+  concentratie  in  het  plasma 
tussen 0.7‐1.1 mmol/L, is van levensbelang. Deze regulatie vindt plaats door Mg2+ opname 
door  de  darm  (absorptie),  uitwisseling  met  botweefsel  en  heropname  door  de  nieren 
(resorptie). Met name dit laatste orgaan handhaaft de Mg2+ concentratie in het bloed door 
de mate van Mg2+ uitscheiding in de urine te bepalen. De menselijke nier bevat ongeveer 1 
miljoen  functionele  eenheden,  de  nefronen.  Elk  nefron  bestaat  uit  een  glomerulus 
(nierlichaam) met daarop aansluitend de tubulus (nierbuis). Gemiddeld wordt 80% van de 




merendeel  van het  gefiltreerde Mg2+ wordt geresorbeerd  in de nierbuis. Onder normale 
omstandigheden  wordt slechts 3‐5% van het Mg2+ filtraat via de urine uitgescheiden. De 
nier beschikt over een groot aanpassingsvermogen om  te  reageren op veranderingen  in 




transcellulair  wordt  geresorbeerd.  Het  epitheliale  Mg2+  kanaal  TRPM6  dat  specifiek  tot 
expressie  komt  in  het  DCT  is  geïdentificeerd  als  poortwachter  van  dit  transport.  De 
afgelopen  jaren  is  de  moleculaire  regulatie  van  TRPM6  duidelijker  geworden  door  de 
ontdekking  en  karakterisering  van  verschillende  bindingseiwitten.  Daarnaast  heeft  DNA 
analyse  van  patiënten met  geïsoleerde  autosomale  recessieve  renale  hypomagnesiëmie 





In dit proefschrift  ligt de  focus op de bestudering van de  (patho)fysiologische  impact 
van  externe  factoren  die  aangrijpen  op  de  Mg2+  balans.  Zo  werd  het  effect  van  de 
geneesmiddelen  cisplatine  en  furosemide  bestudeerd,  alsmede  de  toediening  van 
verschillende hoeveelheden Mg2+  in het dieet, dit alles in muisstudies.   De functie en het 
belang  van  individuele  ‘magnesiotrope  spelers’  en  de  capaciteit  van  de  nieren,  in  het 









Cisplatine  is  een  effectief  geneesmiddel  in  de  strijd  tegen  solide  tumoren  die  zich 
bevinden  in  bijvoorbeeld  de  eierstokken,  baarmoeder,  testis,  hoofd‐hals  of  longen.  Het 
gebruik van dit geneesmiddel wordt echter beperkt door dosis‐afhankelijke niertoxiciteit. 




grondslag  ligt  aan  de  bijwerking  van  het  renale Mg2+  verlies.  Twee  groepen  van  elk  10 
muizen  werden  3‐maal,  eenmaal  per  vier  dagen,  geïnjecteerd  met  cisplatine  of  met 
controle  vloeistof.  De  cisplatine‐behandelde  muizen  ontwikkelden  een  significante 
polyurie,  verlaagde  creatinineklaring  en  een  aanmerkelijk  verlaagde  plasma  Mg2+ 
concentratie,  terwijl  plasma  calcium  (Ca2+),  natrium  (Na+)  en  kalium  (K+)  waarden  niet 
veranderd  waren.  Bepalingen  van  de  24‐uurs  urine  toonden  een  aanzienlijk  verhoogde 
Mg2+,  Ca2+,  Na+  en  K+  excretie  in  de  cisplatine‐behandelde  groep,  terwijl  de  fosfaat  (Pi) 
excretie niet was gewijzigd. De mRNA expressie van TRPM6, de NaCl cotransporteur (NCC) 
en  parvalbumine  (PV)  in  de  nier,  was  significant  verlaagd  in  de  cisplatine  groep.  De 
expressie  van  genen  die  karakteristiek  zijn  voor  andere  delen  van  het  nierbuisje waren 
onveranderd, behalve de expressie van claudine‐16; deze was verhoogd door de cisplatine 
behandeling.  De waargenomen  afname  van  de  hoeveelheid  aan  DCT‐specifieke mRNA’s 
werd bevestigd op eiwitniveau.  
Deze studie heeft het DCT geïdentificeerd als renaal segment dat  in belangrijke mate 
wordt  beschadigd  door  cisplatine.  Aangezien  de  functie  van  het  DCT  essentieel  is  voor 
regulatie  van  de  Mg2+  balans,  verklaart  dit  de  hoge  prevalentie  van  Mg2+  verlies  in 
patiënten  die  met  dit  medicijn  behandeld  worden.  Verder  onderzoek  zal  moeten 
aantonen  waarom  juist  het  DCT  verhoogde  toxiciteit  van  cisplatine  ondervindt; 
bijvoorbeeld door specifieke transporteurs die cisplatine in de cellen van het DCT brengen 
of  doordat  de  relatief  grote  hoeveelheid  mitochondria  dit  deel  van  de  tubulus  extra 
gevoelig maken.  
 
Hoofdstuk  3:  Het  distaal  convoluut  compenseert  voor  furosemide‐geïnduceerd  Mg2+ 
verlies  
Furosemide  is  een  lisdiureticum  dat  de  Na+,  K+,  2Cl‐  cotransporteur  (NKCC2)  in  het  TAL 
blokkeert.  Hierdoor  vermindert  de  resorptie  van  NaCl,  verlaagt  de  lumen‐positieve 
membraanpotentiaal  en  dit  heeft  weer  tot  gevolg  dat  het  paracellulaire  transport  van 
Mg2+  en  Ca2+  afneemt.  Het  directe  effect  van  furosemide  is  dat  het  de  Mg2+  excretie 
vergroot, maar het is niet duidelijk of chronische behandeling tot hypomagnesiëmie leidt. 














Uit  deze  resultaten  kan  de  conclusie  worden  getrokken  dat  tijdens  chronische 
behandeling  met  furosemide,  verhoogde  resorptie  van  Mg2+  via  TRPM6  in  DCT 
compenseert voor de verminderde resorptie van Mg2+  in TAL. Dat soms bij patiënten die 
behandeld  worden  met  lisdiuretica  desondanks  hypomagnesiëmie  wordt 
gediagnosticeerd, heeft waarschijnlijk  te maken met  comorbiditeit of onvoldoende Mg2+ 






via  de  urine  verhoogt.  Ook  is  aangetoond  dat  de  hoeveelheid  Mg2+  in  het  dieet  de 
expressie van TRPM6  in de nier beïnvloedt. Daarnaast kunnen veranderingen  in de Mg2+ 





van de  transcriptiefactoren HNF1B en TRPM6 was verhoogd  in de nier als  reactie op de 
Mg2+  restrictie,  daar waar  andere magnesiotrope  spelers  niet werden beïnvloed. HNF1B 
reguleert de transcriptie van FXYD2, die codeert voor de γ‐subunit van de Na+, K+‐ATPase.  




als  een  Ca2+‐bindend  eiwit  dat  in  de  nier  exclusief  tot  expressie  komt  in  het  DCT. Onze 




essentiële  adaptieve  rol  voor  het  DCT  gedurende  hypomagnesiëmie,  aangezien  TRPM6, 
HNF1B, PV en NCC expressie niveaus waren aangepast. 




eiwitten TRPV5 en  calbindine‐D28K. De  combinatie  van al deze veranderingen  suggereert 














activering  van  TRPM6.  Het  is  aangetoond  dat  de  P1070L  mutatie  in  pro‐EGF  de 
uitscheiding van dit eiwit aan de basolaterale kant van gepolariseerde Madin‐Darby canine 
kidney (MDCK) cellen belemmert. Dit heeft als consequentie dat de EGF receptor (EGFR) in 




die  deze  eiwitten  stabiel  tot  expressie  brengen.  Met  behulp  van  het  induceerbare 
Tetracycline‐gereguleerde  Expressie  (T‐REx)  systeem  werd  het  sorteren  en  splitsen  van 
pro‐EGF  en  de  mutant  bestudeerd  in  gepolariseerde  MDCK  cellen.  Middels 
immunocytochemie  kon worden  aangetoond  dat  pro‐EGF‐WT  en  pro‐EGF‐P1070L  beide 
voornamelijk  aanwezig  zijn  op  de  apicale  membraan.  Verder  zijn  de  zijde‐specifieke 
kweekmedia, die de MDCK cellen op de filters omringen, onderzocht met immunoblotting 
en  enzyme‐linked  immunosorbent  assay  methoden.  Hieruit  bleek  dat  (pro‐)EGF  vooral 
wordt  uitgescheiden  aan  de  apicale  kant  van  de  cel  en  aldaar  gekliefd  wordt  tot  het 
volwassen  6  kD  EGF.  Bovendien  werd  een  verminderde  uitscheiding  van  de  mutant 
zichtbaar  ten  opzichte  van  wild‐type,  in  zowel  het  apicale  als  het  basolaterale 
compartiment. Tot slot,  toevoeging van de metalloprotease remmer phenanthroline had 
geen invloed op de secretie van pro‐EGF.  
Onze  conclusie  is  dan  ook  dat  pro‐EGF‐WT  en  pro‐EGF‐P1070L  voornamelijk worden 
gesorteerd naar de apicale zijde in MDCK cellen en aldaar uitgescheiden en verder gekliefd 
worden.  De  bevindingen  suggereren  verder  dat  de  mutatie  resulteert  in  verminderde 
splitsing  van  pro‐EGF‐P1070L  aan  zowel  de  apicale  als  de  basolaterale  zijde.  De 
hypomagnesiëmie  gediagnosticeerd  in  patiënten  die  aangedaan  zijn  door  de  mutatie 
wordt  waarschijnlijk  veroorzaakt  door  verminderde  stimulatie  van  de  EGFR  aan  de 
basolaterale  zijde.  Dit  doordat  de  drempelwaarde  voor  uitgescheiden  EGF  niet  wordt 




Transcellulaire  Mg2+  resorptie  in  de  nier  is  essentieel  voor  de  Mg2+  homeostase,  zoals 
benadrukt  is  door  de  bestudering  van mutaties  in  verschillende  genen die  tot  expressie 
komen in het DCT en resulteren in hypomagnesiëmie. In dit proefschrift is uiteengezet dat 
het  DCT  over  een  indrukwekkend  aanpassingsvermogen  beschikt  in  reactie  op  externe 
factoren die ingrijpen op de Mg2+ balans. Als het DCT zelf is aangedaan, bijvoorbeeld door 





basolaterale  plasmamembraan  van  het  DCT  onthullen.  Daarnaast  is meer  aandacht  van 
artsen  voor  het  herkennen  en  monitoren  van  patiënten  met  een  verhoogd  risico  op 


























ADAM       a disintegrin and metalloprotease  
ANOVA      analysis of variance  
AQP1       water channel aquaporin 1  
AQP2      water channel aquaporin 2 




[Ca2+]i       intracellular Ca
2+ concentration  
Ca2+      calcium ion  
CaSR       Ca2+‐sensing receptor  
CCr       creatinine clearance rate 
CD      collecting duct 
cDNA       complementary DNA 
cisplatin     cis‐diamminedichloroplatinum(II) 
CKD       chronic kidney disease  
Cl‐      chloride ion 
CLC‐Kb       Cl‐ channel, subunit b  
CLDN7       claudin‐7  
CLDN8       claudin‐8 
CLDN16      claudin‐16  
CLDN19      claudin‐19  
CLSM       confocal laser scanning microscopy   
CNNM2      cyclin M2  
CNT      connecting tubule 
CTR1      copper transporter 1 
 
D 
DCT      distal convoluted tubule  
DCT1      early DCT 
DCT2      late DCT 
DM2      diabetes mellitus type 2 
DMEM       ulbecco’s modified Eagle’s medium  
DNA      deoxyribonucleic acid 
DTT      dithiothreitol 
 
E 
EDTA      ethylenediaminetetraacetate  
EGF       gene encoding pro‐EGF 
EGF       epidermal growth factor 
EGFR       EGF receptor  





ELISA       enzyme‐linked immunosorbent assay  
ENaC       epithelial Na+ channel  
ER      endoplasmic reticulum 
 
F  
FCS       fetal calf serum 
FHHNC       familial hypomagnesemia with hypercalciuria and    
      nephrocalcinosis 
FXYD2      gene encoding the Na+, K+‐ATPase γ‐subunit  
 
G 
GAPDH       glyceraldehyde 3‐phosphate dehydrogenase   
GFP       green fluorescent protein 
GFR       glomerular filtration rate  
GS       Gitelman syndrome  
 
H 
H2O       water  
H2O2       hydrogen peroxide  
HEK293      human embryonic kidney 293 
HNF1B       hepatocyte nuclear factor 1 homeobox B 
HSH       hypomagnesemia with secondary hypocalcemia 
 
I 
ICD       initial CD  
IDH      isolated dominant hypomagnesemia 
IHC       immunohistochemistry 
IMCD       inner medullary collecting duct 
IRH       isolated autosomal recessive renal hypomagnesemia 
 
K 
K+      potassium ion  
kD      kilodalton 
Kim‐1      kidney injury molecule‐1  
Kir4.1       inward rectifier K+‐channel 4.1  
Kir5.1       inward rectifier K+‐channel 5.1  
Kv1.1       voltage‐gated K+ channel 1.1 
 
M 
[Mg2+]i       intracellular Mg
2+ concentration  
MDCK      Madin‐Darby canine kidney 
Mg      magnesium 
Mg2+      magnesium ion 
MgSO4       magnesium sulfate 
mRNA       messenger RNA 









n      number per group 
Na+      sodium ion 
NCC      thiazide‐sensitive Na+, Cl‐ cotransporter  
NCX1      Na+, Ca2+ exchanger  
NHE3       Na+, H+ exchanger 3  
NKCC2      Na+, K+, 2Cl‐ cotransporter  
 
O 
OCT2      organic cation transporter 2  
 
P 
P      probability of events 
P1070L       pro‐EGF mutant  
PAGE      polyacrylamide electrophoresis gel  
PBS       phosphate buffered saline 
pCB7      plasmid CB7  
PCR      polymerase chain reaction  
PCT       proximal convoluted tubule 
PEI       polyethylenimine   
Pi       inorganic phosphate 
PIP2      phosphatidylinositol 4,5‐bisphosphate  
PKA       protein kinase A  
PKA       protein kinase C 
PLP       periodate‐lysine‐paraformaldehyde 
PMA       phorbol myristate acetate  
PMCA1b     plasma membrane ATPase type 1b  
PMSF      phenylmethylsulphonylfluoride 
pro‐EGF      precursor EGF 
PST       proximal straight tubule 
PT       proximal tubule 
PTH      parathyroid hormone  
PV       parvalbumin 
PVDF      polyvinylidene difluoride 
 
Q 
qPCR      quantitative PCR 
 
R 
RAAS       renin‐angiotensin‐aldosterone system  
RACK1       receptor for activated C‐kinase 
RDA      recommended dietary allowance  
REA       repressor of estrogen receptor activity        
RNA      ribonucleic acid 
ROMK       renal outer medullary K+ channel 
RT      room temperature 







SEM      standard error of the mean 
SGLT1      sodium‐glucose cotransporter 1 
SPAK       proline alanine‐rich kinase  
Src       sarcoma 
 
T 
T‐REx       Tetracycline‐Regulated Expression  
TAL      thick ascending limb of Henle’s loop 
TetR       Tet repressor  
TM       transmembrane  
Tris      tris(hydroxy‐methyl)aminomethane  
TBS‐T       Tris‐buffered saline Tween‐20   
TRPM       transient receptor potential channel, subfamily melastatin 
TRPM6      transient receptor potential channel subfamily M, member 6 
TRPM7      ransient receptor potential channel subfamily M, member 7 
TRPV5      transient receptor potential channel subfamily V, member 5 
  
W 













Annelies  van  Angelen  werd  op  27  oktober  1981  geboren  te  Utrecht.  In  2000  werd  het 
atheneumdiploma behaald aan het St. Bonifatiuscollege, te Utrecht. Vervolgens studeerde 
zij Bio‐medische wetenschappen aan de Universiteit van Amsterdam. Tijdens deze studie 
liep  zij  een  korte  stage  bij  het  Interuniversitair  Oogheelkundig  Instituut  (Dr.  M. 
Kamermans)  en  langere  stages  bij  de  afdeling  Celbiologie  (Dr.  A.  Sonnenberg)  van  het 
Nederlands  Kanker  Instituut  en  bij  de  Provincie  Zuid‐Holland  afdeling  Milieubeleid  en 
Luchtkwaliteit  (Drs. C.  van Dam). De Master Bio‐medische wetenschappen werd  in 2007 
succesvol  afgerond.  Daarnaast  behaalde  zij  in  2005  haar  Propedeuse  Geneeskunde  aan 
dezelfde Universiteit. In januari 2008 startte zij als onderzoeker in opleiding bij de afdeling 




Foundation  (EURYI  044.036.001).  Tijdens  deze  periode  heeft  zij  een  Bachelor  student 
begeleid.  Daarnaast  heeft  zij  in  2010  de  cursus  Proefdierkunde  met  goed  gevolg 
doorlopen (Artikel‐9 bevoegdheid). 































N, and Sonnenberg A.  Investigation  into the mechanism regulating MRP  localization. Exp 
Cell Res 314: 330‐341, 2008 














Voilá  mijn  proefschrift!  Promoveren  en  het  leveren  van  sportprestaties  lijken  veel  op 
elkaar.  Het  begint  allemaal  met  goede  voorbereiding,  training,  oftewel  studie  en 
vaardigheden  aanleren  (stages)  en  een  beetje  talent  is  mooi  meegenomen.  Dan  is  het 
belangrijk om een mooi doel voor ogen te hebben waar je wilt  ‘vlammen’; een toernooi, 
wedstrijd  of  dus  een  uitdagende  promotieplaats.  Vervolgens  is  het  belangrijk  om  met 
teleurstelling om te kunnen gaan en juist succes(jes) te vieren, door te zetten en wat geluk 
te  hebben.  Soms moet  je  even  relativeren;  er  is  altijd  een  nieuwe  kans,  wedstrijd,  een 
nieuw  experiment  of  project.  En  net  zoals  sportsuccessen  was  dit  proefschrift  er  niet 
gekomen zonder goede begeleiding, teamwork, trainingsmaatjes of een ‘clubgevoel’. 
 
Ten  eerste wil  ik mijn  promotoren,  Prof.  dr.  René  Bindels  en  Prof.  dr.  Joost Hoenderop 
bedanken. Beste René en Joost, ik heb veel bewondering voor de passie en inzet waarmee 
jullie  leiding  geven  aan  de  afdeling.  Het  lab  en  alles  daar  omheen  is  tot  in  de  puntjes 
georganiseerd, maar even bij jullie binnenlopen kon meestal ook en dat was voor mij heel 










hebben daar  in  ‘t  hoge noorden. Ook  kijk  ik met  veel  plezier  terug  op de  etentjes, met 
onze mannen  erbij.  AnneMiete,  enorm  bedankt  dat  je  altijd  voor mij  klaarstond  om  te 
helpen  bij  dierproeven,  het  doen  van  een  kleuring  of  het  testen  van  antilichamen.  En 
gezellig dat je me ook regelmatig in Arnhem kwam opzoeken. Ik hoop dat je nog lang van 











Bob, wat was  het  fijn  om  jou  in  de Unit  te  hebben;  je  peptalk  heeft me door moeilijke 
momenten geholpen en ik heb veel gehad aan jouw kennis van genetica. Eline, in Arnhem 
wonen schept een band; samen in de trein naar het werk of met de auto naar een feestje. 
Dank  voor  je  luisterend  oor,  belangstellende  mailtjes  en  ik  ben  benieuwd  naar  jouw 






















ik  op  deze  plaats  bedanken,  in  het  bijzonder  Henk,  Janneke,  Jeroen  en  Bianca.  Zonder 







Lisa,  fijn  om met  jou  lief  en  leed  te  kunnen delen. De  skivakanties, weekendjes weg  en 
andere afspraakjes, met Walter ook, waren heerlijke onderbrekingen van het onderzoek 
doen.  Jammer dat we sinds onze studententijd  steeds verder uitelkaar  zijn gaan wonen, 
maar de komende tijd gaat het me vast lukken vaker jullie kant op te komen. Michiel fijn 
dat  jij  mij  wegwijs  wilde  maken  met  de  layout.  Gezellig  dat  we  ondanks  onze  drukke 

























hectiek.  Ik  ben  blij mijn  leven met  jou  te mogen  delen. Myrthe  en  Sacha  jullie  zijn  het 
mooiste ‘resultaat’ van de afgelopen jaren. 
 
  
 
 
 
 
 
 
 
